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ABSTRACT OF THE DISSERTATION 
Biophysical studies of the intracellular domains of the EGFR family of Receptor Tyrosine 
Kinases 
by 
Kwabena Amofa Nketia Sarpong 
Doctor of Philosophy in Biology and Biomedical Sciences 
Biochemistry 
Washington University in St. Louis, 2017 
Professor Ron Bose, Chair 
The epidermal growth factor receptor and its three orthologues, HER2, HER3 and HER4 have 
been the subject of intensive basic, clinical and translational research due to their involvement in 
cancers. These proteins are part of elaborate networks that interact with a myriad of other 
molecules to effect diverse signaling pathways and affect cellular processes such as migration, 
apoptosis, cell differentiation and so on. In addition to the formation of preformed dimers, it is 
well established that ligand engagement leads to receptor dimerization in all family members, 
except HER2. In the past decade, it has been shown that their intracellular domains dimerize in 
xii 
 
an asymmetric fashion where the C-lobe of the donor kinase interacts extensively with the N-
lobe of the receiver kinase. This structural model is critical for activation of the receiver kinase 
and subsequent phosphorylation of the C-terminal tail. While the structures of the different 
domains have been solved, minimum structural and biophysical studies have been performed on 
the C-terminal tails. In this thesis, we use multiple approaches to characterize the C-terminal tails 
of EGFR and HER3, and show that they are intrinsically disordered regions of these receptors. 
We also developed a strategy that has been employed to site-specifically fluorophore-label the 
EGFR kinase domain, and would serve as a biological probe to directly measure EGFR kinase 
domain dimerization on lipid surfaces. 
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Chapter 1: Introduction 
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1.1 EGFR Receptor Tyrosine kinases, an overview 
The isolation of the epidermal growth factor by Stanley Cohen in the 1950s (1) and its 
significance in physiology led to the identification of the epidermal growth factor receptor, 
EGFR, HER or ERBB1 (2). Since then, the EGFR family has grown to include HER2 or 
ERBB2, HER3 or ERBB3 and HER4 or ERBB4 (3). These family of receptor tyrosine kinases 
(RTKs) play significant roles in the normal functioning of the cell. Cellular processes that these 
RTKs regulate include cell migration, proliferation and differentiation, cell survival and 
metabolism, and cell-cycle control. All four family members share a very similar molecular and 
structural architecture; a large ectodomain, that binds of ligand, a single alpha helical 
transmembrane domain, and an intracellular cytoplasmic domain that contains the 
juxtamembrane segment, the kinase domain and an intrinsically disordered C-terminal tail region 
as shown in Figure 1.1 (4-7). Except HER2 which is constitutively active and does not have a 
cognate ligand, the other three members are activated by ligands (epidermal growth factor, 
transforming growth factor, heregulin, amphiregulin and heparin-binding epidermal growth 
factor) (8). HER3 on the other hand has little to no kinase activity and studies have shown that 
HER3 assumes the donor kinase position when in a heterodimeric pair (4,9). Following 
dimerization of the extracellular domains, their intracellular cytoplasmic domains dimerize in an 
asymmetric fashion and activates the receiver kinase. This engages the unstructured C-terminal 
tail and becomes phosphorylated at various tyrosine residues, providing docking sites for Src 
homology 2 or phosphotyrosine-binding signaling molecules to interact (Figure 1.1) (10). The 
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result is the recruitment of other adaptor proteins that signal via different pathways (11-14).
 
Figure 1.1. Structural architecture and mechanism of activation of the EGFR family of 
Receptor Tyrosine Kinases. This figure is adapted from Zahnow, C.A., 2006 (10) 
 
1.2 Role and significance of EGFR family in cancer 
EGFR involvement in cancer surfaced in the 1980s when the erythroblastosis tumor virus was 
shown to encode an abnormal form of EGFR. The EGFR family of receptor tyrosine kinases 
have been implicated in several solid tumors (11). These cancers have often been overexpression 
of the receptors, gene amplification, autocrine loop activation and the presence of activating 
somatic mutations in the EGFR family (15-19). It has been widely known that the HER2-HER3 
signaling is the most potent signaling pair (20), especially in HER2-amplified breast cancers 
where HER3 expression is a requirement for the growth of these cancers. A similar consequence 
is seen in patients with non-small cell lung cancers caused by an activating mutation in EGFR, 
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where studies have shown that suppression of HER3 signaling results in growth suppression (21, 
22). HER3 is now an actively pursued drug target since it provides acquired resistance to 
therapeutics by activating alternative signaling pathways (23). HER3 achieves this by increasing 
outputs in processes such as transcription, translation, phosphorylation and the use of other 
redundant mechanisms which are downstream of its signaling output. Somatic mutations in 
HER3 have recently been published and various groups are actively pursuing the functional 
significance of these mutations (18, 24-26). HER4, on the other hand has not been shown to have 
important roles in cancer, though some studies have reported its involvement in melanoma (27). 
Currently, there are FDA-approved small molecule tyrosine kinase inhibitors such as lapatinib 
and antibody-based therapeutics such as trastuzumab and pertuzumab that target EGFR and 
HER2-driven cancers (28-30). 
1.3 Structural analysis of the kinase domain of the EGFR family 
The structural organization of EGFR and its three orthologues (HER2, HER3 and HER4) is 
strikingly similar; they all possess a large extracellular domain that binds to ligand, a single 
alpha-helical transmembrane domain and an intracellular cytoplasmic domain that contains the 
kinase domain and the intrinsically disordered C-terminal tail (4-7). The extracellular domain is 
organized into 4 subdomains. While subdomains I and III are rich in leucine repeat motifs, 
subdomains II and IV contain C-C disulfide-rich bonds. In the absence of ligand, EGFR, HER3 
and Her4 receptors exist in a closed, tethered conformation that is mediated by interactions 
between domains II and IV. EGF (or other cognate ligands) binding leads to an alteration in the 
structure of the extracellular domain to create a ligand-binding pocket and the protrusion of a 
dimerization arm (from subdomain II). Homo- and heterodimerization is facilitated by 
interactions with the dimerization arm (31). HER2 does not require ligand binding to achieve an 
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active conformation and its extracellular domain is poised in a fixed, activated state even when 
monomeric, rendering HER2 permanently available for dimerization (32). There are dimer 
contacts in the extracellular and intracellular regions as well as the transmembrane helix, though 
not coupled together (33). The kinase domain consists of the N-terminal and C-terminal lobes. 
Several lines of evidence show that the kinase domain dimerizes in an asymmetric fashion; 
where the C-lobe of the donor kinase makes extensive contacts with the N-lobe of the receiver 
kinase. In this model,  (figure 1.2) the receiver kinase becomes activated and phosphorylates 
tyrosine residues in the C-terminal tail, which serve as docking sites for phosphotyrosine-binding 
proteins and SH2 domains (4). The activation process is sequential and dependent on the 
enzymatic kinase activity of the receptor (34).  Other critical regions in the kinase domain 
include the activation loop and the C helix, both of which adopt different conformations when 
in an active or inactive state (35). The formation of the asymmetric dimer means that specific 
mutations at the interface can compromise the catalytic activity of the kinase (4, 36).  
 
Figure 1.2. Model of the EGFR asymmetric kinase domain dimer. This figure is adapted 
from Zhang et. al, 2006 (4) 
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1.4 Inhibition of the kinase domain by small molecules and Mig6 
Since the discovery of their involvement in cancer, a variety of therapeutic strategies have been 
developed to target EGFR family of proteins-driven tumors. This has been achieved by using 
monoclonal antibodies such as pertuzumab, trastuzumab and others that bind to the ectodomain 
and interfere with signaling. These antibodies are either used singly or in combination, where 
their proposed mechanism of action is bind to subdomain II or IV resulting in the inhibition of 
dimerization and blocking of ligand-dependent and ligand-independent signaling (37). Recently, 
alternative approaches have been investigated and resulted in the use of ATP-competitive small 
molecules to inhibit the kinase domain (30). While some of these kinase domain inhibitors 
possess a reversible mode of action, others such as neratinib attaches irreversibly to the cysteine 
residue close to the ATP binding domain and results in the complete shutdown of the kinase 
activity of the receptor (28). Although enormous success has been achieved by targeting the 
extracellular and kinase domains, the emergence of drug resistance has necessitated the 
development of new targets and better therapies for these EGFR-driven cancers (38). The 
formation of an asymmetric dimer is critical for activation of the kinase and downstream 
signaling. This dimer interface presents a crucial target that can be exploited for development of 
drug candidates to inhibit EGFR signaling. Indeed, there is an endogenous protein, Mig6 
(Mitogen-induced gene 6) that is known to bind to the kinase domain and inhibit its activity. 
Structure-based methods have shown that Mig6 binds to the distal surface of the C-lobe of the 
kinase domain and thus prevents the formation of an asymmetric dimer (39). The Bose lab and 
other research groups are actively pursuing the use of the Mig6 peptide (and its other mutants) to 
inhibit dimerization and block signaling (unpublished data).  
1.5 Regulation of EGFR signaling by the C-terminal tail 
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The intracellular domain of EGFR (and its three orthologues) consist of the membrane proximal 
juxtamembrane segment, the kinase domain and a C-terminal tail that contains more than 200 
residues. Composite analysis has shown a <25% sequence similarity among the four EGFR C-
terminal tails. Upon dimerization and activation, the C-terminal tail interacts with the active site 
of the kinase domain and results in the phosphorylation of the tyrosine residues (11). The 
phosphorylated tail serves as a docking site for binding by phosphotyrosine binding proteins and 
other proteins that contain SH2 domains (40). In addition, phosphatases can dephosphorylate the 
C-terminal tail (41, 42). This cycle of events compels the C-terminal tail to adopt a variety of 
conformations that allows it to interact efficiently with its different partners under various 
conditions. It wasn’t until recently that structural and biophysical approaches begun to shed light 
on our understanding of the C-terminal tail (43-45). Experimental and in silico approaches have 
shown that the C-terminal tail of EGFR and HER3 are intrinsically disordered, and possess a 
larger apparent molecular size compared to a globular protein of similar molecular weight (45). 
Crystal structures containing residues 982-1022 of the C-terminal tail of EGFR have suggested a 
negative inhibitory role for the C-terminal tail. In this model, the proximal residues of the C-
terminal tail form an alpha helix (residues 997-1001) that stabilizes the inactive dimer, while the 
acidic residues (Electrostatic hook, residues 1003-1014) and distal residues (1015-1022) that 
form a beta strand prevents the formation of the juxtamembrane latch necessary for activation 
(46). This finding is buttressed by another study where the authors identified residues 982-1054 
in the proximal region of the C-terminal tail that inhibit the formation of an asymmetric dimer 
(47) 
1.6 Protein intrinsic disorder and role in diseases 
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Intrinsically disordered proteins (IDPs) are regions or domains that do not have stable secondary 
or tertiary structures. Nonetheless, these regions maintain the ability to function in cellular 
processes including regulation of transcription, signaling, protein-protein interactions, cell life 
cycle events etc. They perform these roles due to their ability to adopt different conformations 
under different conditions and due to their structural flexibility (48-55). This results in IDPs 
having to fold and assume different conformations when interacting with different partners. 
Misfolding of these regions ultimately leads to the formation of unwanted aggregates and 
complexes which do not possess the structural and functional integrities to undertake their roles 
thereof. The proteomes of eukaryotes are replete with intrinsically disordered regions, where 
most of these proteins contain long stretches of disordered regions or the whole protein is almost 
completely disordered (56). Using PONDR VL-XT disorder predictor algorithm to analyze 
protein datasets, it has been suggested that there is a strong correlation between protein intrinsic 
disorder and their roles in signaling and cancer (57). Most importantly, in silico and experimental 
data have revealed many protein kinases contain intrinsically disordered regions, which facilitate 
their interactions with other proteins and enhance their signaling outputs (58).  
1.7 Biophysical approaches for studying intrinsically disordered proteins 
Though intrinsically disordered proteins might be accorded unstructured properties in protein 
chemistry, their functional properties provide enormous suggestion that their structural 
organization is intimately related to the cellular processes they are involved in. Traditional and 
classical methods such as Nuclear Magnetic Resonance and X-ray Crystallography were mainly 
developed to study proteins that form stable structures. Due to their structural and other inherent 
physical properties, it is often very difficult to obtain high concentrations or representative 
crystal structures of IDPs to enable their study using these traditional methods (51, 53). In the 
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past few years, there have been considerable efforts to develop methods to study the behavior of 
IDPs. Scattering approaches such as Dynamic and Light Scattering, Small Angle X-ray 
Scattering and Small Angle Neutron Scattering in combination with Analytical 
ultracentrifugation and Size Exclusion Chromatography have been used extensively to assess the 
size and shape of proteins (59-63). These methods can provide quantitative measurements such 
as the hydrodynamic radius, radius of gyration, stoke radius on IDPs under solution conditions. 
Because of their highly dynamic and flexible nature, experimental and molecular dynamics 
methods have been and are still being developed to analyze the conformational behavior of IDPs. 
Lastly, temperature, pH and denaturant-induced changes together with single-molecule 
Fluorescence Resonance Energy Transfer and Hydrogen-Deuterium exchange with mass 
spectrometry have spearheaded experimental approaches that are utilized to assess the 
conformational transitions of IDPs (64-68) 
1.8 Site-specific modification of proteins 
Biotechnological and biochemical applications are becoming increasingly dependent on 
derivatized proteins. These modified proteins provide excellent avenues for studying protein-
protein and protein-ligand interactions, folding, post-translational modifications, conformational 
changes and further interrogating the functions of proteins both in vivo and in vitro. The past few 
decades have seen the development of several protein engineering strategies to site-specifically 
modify proteins by employing distinct chemistries and utilizing the specificities of various 
enzymes (69, 70). Most commonly used chemical handles for protein modification include 
fluorescent tags, chemical cross linkers, biotin, carbohydrates, nucleic acids and so on.  Due to 
their low abundance in the proteome, cysteines have traditionally been employed via maleimide 
chemistry to label proteins (71). Other methods have exploited the reactive N-terminal amino 
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group and the -amino group of lysines to selectively attach N-hydroxysuccinimidyl esters to 
proteins. In addition, chemical labeling strategies have been developed to modify tyrosine, 
aspartate and glutamate residues. Chemoenzymatic approaches, on the other hand utilize a 
variety of enzymes to recognize a specific engineered motif on the protein and attach a chemical 
handle onto the protein.  Enzymes such as lipoic acid ligase, biotin ligase, sortase, 
phosphopantetheinyltransferase among others have been employed to selectively label different 
proteins (72). Such tag-mediated protein labeling approaches should (i) be fast, robust and 
quantitative, (ii) be highly selective and specific, (iii) have minimum structural and functional 
consequences (iv) short reaction times and (v) result in the formation of a stable, covalent bond 
between the protein and the desired moiety. Although not a single method can satisfy all these 
requirements, the bottlenecks associated with these labeling methods include the tolerance of the 
proteins to incorporate the recognition motif and the difficulty in removing unmodified proteins 
prior to their use.  
1.9 The use of sortase to efficiently label proteins 
Sortases are membrane-associated transpeptidases that anchor Gram-positive bacterial surface 
proteins to their cell walls. Due to their significance in virulence, sortases might be considered as 
strong drug targets for fighting bacterial infections. Although there are four subfamilies of 
sortases (subfamily A – D), sortase A has been the prototypical member that has been studied 
extensively and employed for a myriad of biophysical applications. Sortase A is more versatile 
and accepts a variety of protein substrates as compared to the other family members. 
Mechanistically, sortase A cleaves the threonine-Glycine bond on any protein that contains the 
sortase A recognition motif, Leu-Pro-Xxx-Thr-Gly (LPXTG, where X can any amino acid, 
preferably glutamate). This leads to the formation of an acyl-enzyme intermediate, which is 
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resolved by the nucleophilic attack of an oligoglycine peptide. In bacteria, the resulting 
oligoglycine-protein complex becomes incorporated and displayed on the cell wall, as shown in 
figure 1.3 (73-77). Because the oligoglycine and LPXTG motifs can be easily synthesized or 
engineered into proteins, sortase A has been used in a variety of ways to modify any protein of 
interest with different chemical handles. One important advantage in using sortase for protein 
labeling is its ability to modify proteins at the C- and N-termini, and also on internal loop regions 
(76, 77). Sortase-mediated reactions are known to be highly specific and result in higher yields 
of the labeled protein. As a result, sortase has been utilized to label proteins in solution, in cell 
lysates and on the surface of living cells. 
 
Figure 1.3. Sortase-mediated anchoring of proteins to bacterial cell wall. Adapted from 
Guimaraes et. al, 2013 (77) 
 
1.10 Conclusion 
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In conclusion, EGFR and its three orthologues have been primary targets for drug developments 
for nearly four decades, because of their involvement in tumorigenesis. From a research 
perspective, the common structural organization of this family of receptor tyrosine kinases 
allows studying their modular domains in isolation. This helps to build a robust composite 
structural picture of EGFR, and stimulate investigation of how the various domains function 
together in signaling. The discovery in 2006 by the Kuriyan group, that the formation of an 
asymmetric dimer by the kinase domains was needed for activation, was very critical in shaping 
our understanding of the mechanistic details of EGFR signaling. The field has been fortunate to 
gain detailed insights on the structural basis of activation and how specific regions such as the 
juxtamembrane domain and transmembrane contribute to dimerization. Nonetheless, we still do 
not have a general platform that allows the direct measurement of dimerization of the kinase 
domains on lipid membranes, which would be instrumental in determining quantitative 
parameters that govern EGFR kinase domain dimerization. Such studies would also allow us to 
answer questions pertaining to how cancer-associated mutations affect dimerization. In addition, 
the C-terminal tail of these proteins have not been extensively studied to determine its 
significance in dimerization. This is in part due to the absence of enough biophysical and 
structural studies on the EGFR C-terminal tails. As such, the next three chapters of this thesis 
attempts to address two pertinent questions in the field: (i) what are the structural and 
biophysical characteristics of EGFR and HER3 C-terminal tails and (ii) can we develop a robust 
strategy to directly measure EGFR kinase domain dimerization on lipid surfaces. 
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2.2 ABSTRACT 
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases include 
oncogenes important in the progression of breast and other cancers, and they are targets for many 
drug development strategies. Each member of the ErbB family possesses a unique, structurally 
uncharacterized C-terminal tail that plays an important role in autophosphorylation and signal 
propagation. To determine whether these C-terminal tails are intrinsically disordered regions, we 
conducted a battery of biophysical experiments on the EGFR and HER3 tails. HDX-MS 
experiments (performed by Ted Keppel, Bose lab) on the intracellular domain of EGFR, HER2 
and HER3 had shown a rapid exchange behavior of the C-terminal tails compared to the kinase 
domains, which is characteristic of a highly dynamic and/or frequently exchange-competent 
conformational state. We expressed and purified recombinant EGFR and HER3 C-terminal tail-
only constructs. Results from circular dichroism spectroscopy, size exclusion chromatography 
with multiangle light scattering, dynamic light scattering, analytical ultracentrifugation, and 
small angle X-ray scattering each provide evidence that the EGFR and HER3 C-terminal tails are 
intrinsically disordered with extended, non-globular structure in solution. The intrinsic disorder 
and extended conformation of these tails may be important for their function by increasing the 
capture radius and reducing the thermodynamic barriers for binding of down- stream signaling 
proteins.  
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2.3 INTRODUCTION 
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases 
(RTKs) contains four member proteins: EGFR/ErbB1, HER2/ErbB2/neu, HER3/ErbB3, and 
HER4/ErbB4. These RTKs carry out important signaling functions via the sequential process of 
ligand binding by the extra- cellular domain, homo- or heterodimerization, activation of their 
intracellular kinase domain, and recruitment of down- stream signaling proteins. These RTKs are 
also important oncogenic drivers in many breast, lung, and other human cancers (78). Several 
structural biology studies on the ErbB family have been published, and this has helped advance 
drug development for HER2-positive breast cancer (79). Protein crystallography studies 
published in 2004 showed the structure of pertuzumab bound to the extracellular domain of 
HER2 and lapatinib bound to the kinase domain of EGFR (80, 81). Since that time, growing 
structural biology-based understanding of how EGFR, HER2, and HER3 function at the atomic 
level has dramatically reshaped our understanding of RTKs (78, 79). Despite these advances, 
there is a domain in each EGFR/ErbB family protein for which little structural biology 
information is available; this domain is the C-terminal tail (CTT) domain. The CTTs contain 
numerous autophosphorylation sites that are essential for recruiting downstream signaling 
proteins and initiating intracellular signaling (43, 82). The CTT can also contribute to 
autoinhibition of the kinase domain of RTK (83). The lack of available crystallographic 
information on the CTT region of EGFR/ErbB family RTKs led us to examine whether these 
proteins lack a stable secondary and/or tertiary structure.  
Intrinsically disordered regions (IDRs) represent an emerging area of interest in 
medicine. IDRs are regions within proteins that exhibit high flexibility and may lack a secondary 
or tertiary structure but are still able to carry out important biological functions (48-55). 
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Algorithm prediction methods indicate that around 25–30% of eukaryotic proteins can be 
categorized as having disordered regions (56). These disordered regions provide certain 
advantages in protein-protein interactions, including a larger hydrodynamic radius (84, 85), 
faster on- and off-rates of binding (86), high binding specificity (87), and the ability to adopt 
different conformations depending on the binding partner (49,88). Correlation studies have 
revealed a high propensity for disordered regions to undergo post-translational modification, 
particularly phosphorylation (89). Because traditional methods, such as NMR and X-ray 
crystallography, were developed to study stable protein structures, IDRs have been more difficult 
to analyze because of difficulties in obtaining high concentrations or representative protein 
crystals (51, 90). Correlation studies suggest a strong association between IDRs and human 
cancer-associated proteins (57); therefore, identifying and analyzing IDRs in cancer-related 
proteins is vital in understanding how they function.  
Protein kinases demonstrate a high degree of specificity in facilitating phosphorylation; 
however, many can perform such interactions with multiple substrate partners (91). An analysis 
of the human kinome shows that as many as 83% of kinase genes contain IDRs, which could 
facilitate these multiple interactions. RTKs are involved in more protein-protein interactions than 
any other kinase group, thus potentially pointing to the involvement of IDRs in their recognition 
mechanisms (58). Multisequence alignment (92) of EGFR/ErbB family RTKs shows that the 
kinase domain sequences are highly conserved between all four family members. However, the 
CTT regions are highly divergent between each EGFR/ErbB family member. One previous study 
using circular dichroism (CD) spectroscopy indicated that the EGFR CTT is rich in -helical and 
-sheet content (43), but a later study used coarse grained modeling to show many possible 
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conformations of the EGFR CTT based on the assumption that it is naturally disordered (44). A 
high degree of flexibility in the CTT would provide distinct advantages to EGFR interaction with 
downstream Src homology 2 (SH2) and phosphotyrosine-binding domains during signaling 
functions (43).  
In this work, we examine the biophysical properties of the CTT of EGFR and HER3. The 
motivation of this study is to gather structural information on the CTT region to determine 
whether the tails are highly dynamic, disordered regions. We expressed and purified EGFR and 
HER3 CTT-only constructs and demonstrated that they are functional because they are 
recognized and phosphorylated by EGFR family kinases and once phosphorylated can be bound 
by the Grb2 SH2 domain. Using these CTT constructs, we performed multiple biophysical 
analyses, including CD spectroscopy, size exclusion chromatography with multiangle light 
scattering (SEC-MALS), dynamic light scattering (DLS), analytical ultracentrifugation (AUC), 
and small angle X-ray scattering (SAXS). The results of these methods support the hypothesis 
that the EGFR and HER3 CTTs are IDRs with extended, non-globular structure in solution. 
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2.4 METHODS 
Plasmids 
DNA encoding residues 696–1022 of the human epidermal growth factor receptor was cloned 
into pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites. This EGFR 
wildtype kinase domain construct contains an N-terminal 6-His tag, a linker, and a TEV protease 
cleavage site (MSYYHHHHHHDY DIPTTENLYFQGAM). For the EGFR CTT cloning, DNA 
encoding residues 961–1186 of the human EGFR was cloned into a pET30b vector (Addgene) 
using NdeI and XhoI restriction sites in-frame with a C-terminal His tag in the vector. Similarly, 
DNA encoding residues 981–1342 of the human epidermal growth factor receptor 3 (HER3) was 
cloned into a pET30b vector (Addgene) using NdeI and XhoI restriction sites in-frame with a C-
terminal His tag in the vector. pGEX Grb2- SH2 (amino acids 58 –159) was purchased from 
Addgene (plasmid 46440, deposited by Dr. Bruce Mayer). All plasmids were confirmed by DNA 
sequencing. 
Expression and purification of EGFR kinase domain:  
The protein expression procedure was adapted from protocols described previously (4, 36). 
Recombinant bacmid (Bac-to-Bac expression system, Gibco BRL) were transfected into 
Spodoptera frugiperda Sf9 cells to produce recombinant baculovirus, which were used to infect 
Sf9 cells grown at 27 °C and 120 rpm in IPL-41 medium (Invitrogen) supplemented with 10% 
bovine calf serum supplemented (Hyclone), yeastolate extract (Invitrogen), penicillin, 
streptomycin, and Pluronic F-68. Cultures at a density of 1 x 10
6 
cells/ml were infected at 1 MOI 
and cells were harvested 48 – 72hours post infection by centrifugation at 6000 rpm and 
resuspended in Buffer A (25 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM imidazole, 5% 
glycerol, 1 mM DTT) supplemented with phenylmethylsulfonyl fluoride, benzamidine, DNase, 
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and protease inhibitor mixture tablets lacking EDTA (Roche). The cells were homogenized using 
a probe sonicator and the lysate was centrifuged at 20000 rpm for 45 mins. 0.5 - 0.75 ml of Ni-
NTA beads (Qiagen) were added to the supernatants and incubated on a rotator for 1 h at 4 °C. 
The beads were poured into a 10-ml disposable column (Bio-Rad) and the flow-through 
collected. The column was washed with 10 column volumes of Buffer A + 20 mM imidazole, 
and the proteins were eluted with Buffer A + 50–125 mM imidazole. The eluted fractions were 
further purified by gel filtration chromatography on a Superdex 200 GL 10/300 column (GE 
Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer. Pooled fractions 
were concentrated and treated with TEV protease (at a mass ratio of 1mg of TEV protease to 
40mg of EGFR kinase domain) overnight at 4C to remove the N-terminal His-tag. This was 
bound to Ni-NTA beads and the flow-through was concentrated, snap frozen, and then stored 80 
°C. 
Expression and purification of EGFR CTT and HER3 CTT:  
The E. coli strain BL21(DE3) was used for expression of the EGFR CTT construct. Transformed 
cells were grown in Luria-Bertani medium containing 50 g/ml kanamycin at 37 °C until an 
OD600 of between 0.5 and 0.8 was reached. Expression was induced through the addition of 0.5 
mM isopropyl -D-1-thiogalactopyranoside (IPTG) for 3 h at 37 °C. Bacterial cells were 
centrifuged at 6000 rpm, and the pellets were frozen. Cell lysis was performed at 4 °C with a 
probe sonicator on frozen pellets using Buffer A (50 mM sodium phosphate, pH 8.0, 300 mM 
NaCl, 20 mM imidazole, 1mM DTT) supplemented with 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1mM -mercaptoethanol, Roche Applied Science protease inhibitor mixture tablets, 4 
mM benzamidine HCl. The lysate was clarified by centrifugation at 48,000 x g for 30 min at 4 
°C. Purification was performed using Nickel-chelating chromatography followed by gel filtration 
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chromatography on a Superdex-75 column. The protein was concentrated to 5 mg/ml in 20 mM 
phosphate, 150 mM sodium chloride, pH 8.0. Aliquots were snap frozen in liquid N
2 and stored 
at -80 °C. Protein concentration was determined using UV-visible spectroscopy with a molar 
extinction coefficient of EGFR CTT at 280nm of  = 18,910 M-1cm-1. For specific subsequent 
applications, the addition of tris(2-carboxyethyl) phosphine to EGFR CTT samples was critical. 
A similar procedure was followed to express and purify the HER3 CTT but had trouble using 
BL21 DE3 cells to express the construct. We used BL21 DE3 Rosetta cells to express milligram 
amounts of the HER3 CTT. The use of the codon-optimized Rosetta cells was critical in 
successful expression of the HER3 CTT. This was purified at a concentration of 2 mg/ml in 
20mM Tris, 300mM sodium chloride, 5% (w/v) glycerol, pH 8.0. HER3 CTT concentration was 
determined using a molar extinction coefficient at 280nm of = 25,245 M-1cm-1.  
C-terminal Tail Function via Western Blotting Analysis:  
EGFR CTT was phosphorylated via a reaction in 0.1 mM ATP, 0.1 mM sodium orthovanadate, 1 
mM DTT and 1 mM MnCl
2 catalyst. EGFR CTT concentrations of 0.25 M and 0.50 M tail 
were incubated in the presence of 0.50 M EGFR kinase domain. Two negative controls were 
also incubated under the same conditions with the following exceptions: 0.50 M CTT was 
incubated without kinase domain present, and separately 0.50 M kinase domain was incubated 
without CTT present. A positive control of ATP phosphorylation of 0.50 M EGFR ICH 
construct, which contains both kinase domain and CTT regions together, was also incubated. 
Two EGFR tail region-specific phosphotyrosines were analyzed by Western blotting. Following 
the phosphorylation reaction, EGFR CTT samples were separated by SDS-PAGE on a 10% 
polyacrylamide gel followed by electroblotting onto nitro-cellulose membrane. Two anti-EGFR 
phosphotyrosine primary antibodies were used in separate Western blotting analyses: 1:1000 
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anti-EGFR Tyr(P)-1068 and 1:5000 anti-EGFR Tyr(P)- 1173. Secondary antibody was 1:5000 
anti-rabbit in both blots. The results of the Western blotting analyses are shown in figure 2.2. 
The positive control was also analyzed on the same two Western blots as the EGFR CTT 
samples. Bands from this positive control were observed on both Western blots but are not 
shown herein. HER3 CTT was phosphorylated via the same buffer conditions as the EGFR CTT 
above. HER3 CTT at 0.50 M was incubated in the presence of 0.50 M EGFR or 0.50 M 
HER2 kinase domains. Negative controls were incubated under the same conditions where only 
CTT or kinase domain was incubated in each case. Positive controls pairing HER3 ICH with 
EGFR kinase domain or HER2 kinase domain were also incubated. Samples were separated by 
SDS-PAGE and electroblotted onto nitrocellulose membrane. 1:1000 anti-HER3 Tyr(P)-1289 
primary with 1:10,000 anti-rabbit secondary antibodies were used for the first blot. A 1:1000 
general anti-phosphotyrosine anti- body, PY20, was used for the second blot with 1:10,000 anti- 
mouse secondary antibody. The two Western blots are shown in figure 2.2.  
GST-Grb2-SH2 Expression and Purification: 
BL21(DE3) cells were transformed, and a colony was picked and used to inoculate a 100 ml LB 
ampicillin culture. The culture was induced to mid log phase with 1 mM IPTG for 2 hours at 37 
°C. Pellets were collected and subsequently frozen at -80 °C. GST-Grb2-SH2 was purified using 
glutathione-agarose beads (Sigma). Fractions were eluted with reduced glutathione, pooled, 
dialyzed, and concentrated using an Amicon 10,000 molecular weight cutoff spin concentrator in 
20mM Tris-HCl, pH 8 (4 °C), 150mM NaCl, 1mM DTT. Aliquots were flash frozen and stored 
at -80 °C.  
Interaction of Phosphorylated EGFR CTT and GST-Grb2- SH2 by Pulldown Assay: 
EGFR CTT was phosphorylated by EGFR KD in vitro for 60 min at room temperature. 10 g of 
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GST-Grb2-SH2 was prebound to a 10 l bed volume of glutathione-agarose beads. 2 g of either 
phosphorylated CTT or non-phosphorylated CTT was added to the beads in a volume of 100 l 
of buffer and incubated for 2 hours at 4 °C. Beads were then spun briefly and the flow-through 
(FL) was collected. This was followed by two washes with buffer. Beads (bound) and aliquots of 
the FL were then boiled in SDS-PAGE sample buffer. Western blotting was done on the 
fractions using anti-His6-HRP antibody (Thermo Fisher, MA1-21314-HRP) as a probe.  
Circular Dichroism Spectroscopy: 
EGFR CTT protein was prepared at a concentration of 5 M in 10 mM sodium phosphate, pH 
7.4, 5 mM NaCl. HER3 CTT was also prepared at the same conditions. A 0.1-cm path length 
quartz cell was used for samples and buffer blanks. Cells were placed in a Jasco CD 
spectrometer set at room temperature. The cell in the CD spectrometer was allowed to equilibrate 
for 15 min with nitrogen flowing into the CD spectrometer before scans. The CD spectrometer 
scanned from 260 to 190nm at 20 nm per min. Five individual scans were averaged, and the 
buffer blank was subtracted before analysis. The CD spectra were analyzed on the DichroWeb 
online analysis website (93, 94). The method chosen for this analysis used the CDSSTR 
algorithm with reference database 7 as the reference protein set (95-98). Secondary structure 
assignment was divided into six categories: regular -helix (R), distorted -helix (D), R,D, 
turns, and unordered. CDSSTR structure assignment results are presented in figure 2.3C.  
Size Exclusion Chromatography with Multiangle Light Scattering: 
100 l of EGFR CTT or HER3 CTT (A280 ~ 1) was loaded onto a pre-equilibrated Superdex-75 
10/300 GL (GE Healthcare) column. Elution buffer of 20 mM sodium phosphate, pH 8.0, 
150mM NaCl, 0.5mM DTT was used for EGFR CTT, and 20mM Tris, 300mM sodium chloride, 
5% (w/v) glycerol, pH 8.0 was used for HER3 CTT. The buffer flow rate was 0.5 ml/min for the 
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EGFR CTT and carbonic anhydrase elutions. For the HER3 CTT and EGFR KD elutions, the 
buffer flow rate was 0.3 ml/min. The column was coupled to a Wyatt Optilab rEX and Dawn 
Helios II, which are refractive index and multiangle light scatter detectors, respectively. 
Carbonic anhydrase was used as a globular reference for the EGFR CTT elution because of the 
similar molecular weights of the proteins. Similarly, the EGFR KD was used as a reference for 
the HER3 CTT elution. Astra (Wyatt) software was used to calculate the molar mass.  
Dynamic Light Scattering: 
EGFR and HER3 CTT samples at a concentration of 0.5 mg/ml in 20 mM Tris, 150 mM NaCl, 1 
mM DTT, pH 8.0, were centrifuged for 5mins. 12 l of sample was aliquoted into a clean 
microcuvette, which was placed into a Wyatt Dynapro MSX. The cuvette was equilibrated for 5 
min at 25 °C before data acquisition. BSA was used as a standard at 1.0 mg/ml in the same 
buffer. Dynamics software was used to determine the radius of the protein.  
Analytical Ultracentrifugation: 
Samples were dialyzed against Buffer A (20 mM sodium phosphate, pH 8.0, 150 mM NaCl, 1 
mM DTT) for EGFR CTT or Buffer B (20mM Tris, 300mM sodium chloride, 5% (w/v) glycerol, 
1 mM DTT, pH 8.0) for HER3 CTT at 4 °C overnight. The samples and buffer were recovered 
and briefly centrifuged before loading into centrifuge cells. The cells were balanced and then 
placed in an eight-position rotor, which was put into a Beckman XLA ultracentrifuge. The speed 
was 42,000 rpm, and the temperature was 25 °C. The SEDFIT program was used to analyze the 
data, and the resulting c(s) analysis is shown in figures 2.4E and F (99).  
Small Angle X-ray Scattering Analysis: 
SAXS experiments were performed on the SIBYLS beamline 12.3.1.2 at the Advanced Light 
Source, a national user facility operated by the Lawrence Berkeley National Laboratory 
26 
 
(Berkeley, CA) and supported by the Director, Office of Science, Office of Basic Energy 
Sciences of the United States Department of Energy under Contract DE-AC02-05CH11231 
(100). To optimize the data quality and minimize radiation damage, exposure series of 0.5, 1, 2, 
and 5 sec were performed. The concentration of EGFR CTT (20 mM phosphate, pH 8.0, 150 
mM NaCl) used for these experiments ranged from 0.9 to 3.7 mg/ml. BSA in 20 mM phosphate, 
pH 8.0, 150 mM NaCl was used as a standard in the range of 1.0 –3.0 mg/ml. The concentration 
of HER3 CTT (20mM Tris-HCl, pH 8.0, 300mM NaCl, 5% glycerol, 1 mM DTT) ranged from 
0.9 to 1.5 mg/ml. A minimum of three different concentrations for each protein were used for 
data collection, and five different concentrations were used for EGFR CTT. The data sets were 
processed using standard procedures for ATSAS programs (101). At low angles, the scattered 
intensities of EGFR CTT and HER3 CTT were very well approximated by the Guinier law, 
whereas HER3 CTT showed signs of radiation damage at 5 sec exposures. Before further 
analysis, the scattering curves, free of radiation damage, from a given type of sample with the 
same protein concentration but different exposure times were merged with either PRIMUS (101) 
or SCÅTTER (SIBYLS Beamline at Lawrence Berkeley National Laboratory) and then averaged 
among the same type of sample after normalization using their individual protein concentration. 
The average scattering curves are presented in figures 2.5A and 2.6A. The Rg from data sets free 
of radiation damage was calculated using AutoRg and is presented in Table 2.2. We evaluated 
the molecular weight of the sample by comparing the forward scattering I(0) with that from a 
reference solution of BSA. The Rg and Dmax values for EGFR kinase domain (Protein Data Bank 
code 1XKK) were calculated using the program CRYSOL (102). The pair distribution functions 
for EGFR CTT and BSA were generated using Datgnom (101).  
 
27 
 
2.5 RESULTS  
Disorder Predictions on EGFR, HER2, and HER3 
We used computation algorithms to provide an initial survey of disordered regions in the 
EGFR/ErbB family of RTKs. Predictor of natural disordered regions (PONDR) is a collection of 
algorithms that use an amino acid sequence to predict native disorder (103,104). The VL-XT 
algorithm assigns a disorder propensity score for disorder on a residue by residue basis (101-
105). The VL-XT prediction for EGFR, HER2, and HER3 can be seen in figure 2.1. PONDR 
scores greater than 0.5 indicate predicted disorder, and scores less than 0.5 indicate predicted 
order. Kinase domains of the three EGFR/ErbB family members show mostly predicted order, 
whereas the CTT in each shows large regions of predicted disorder. The amino acid composition 
of the CTT and kinase domains of both EGFR and HER3 is shown in Table 2.1. When 
comparing the CTTs with the kinase domains in both proteins, we observe that the CTTs are 
more enriched in polar, uncharged residues and prolines but relatively depleted in hydrophobic 
residues. For EGFR, polar, uncharged residues make up 30.1% of the CTT versus 14.9% of the 
kinase domain. Prolines make up 10.6% of the EGFR CTT versus 5.4% in the kinase domain, 
and hydrophobic residues (excluding tyrosine, which can become phosphorylated) are 27.4% of 
the EGFR CTT versus 38.9% of the kinase domain (Table 2.1). Similar values are seen with 
HER3 CTT (Table 2.1) despite its primary sequence divergence from EGFR CTT (22% 
sequence identity between EGFR and HER3 CTT; calculated with Clustal Omega) (106). The 
lowered hydrophobicity provides a simple explanation as to why the tails would not form a 
hydrophobic core and therefore be disordered in an aqueous environment. These predictions are 
a useful tool for gaining a general view of disordered regions in a protein sequence, but direct 
empirical evidence would better support the hypothesis of the CTTs as being IDRs.  
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Figure 2.1. Disorder prediction by PONDR VL-XT algorithm. Shown are the disorder 
predictions for EGFR, HER2, and HER3 ICD construct sequences. In all three graphs, results for 
the kinase domain residues are colored blue, and the tail domain residues are colored in red. A 
score above 0.5 indicates predicted disorder while a score below 0.5 indicates predicted order. 
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Table 2.1. EGFR and HER3 amino acid composition analysis by region 
 
Expression of EGFR and HER3 C-terminal Tails 
To further characterize the conformational and physical state of the EGFR and HER3 CTTs, we 
expressed and purified EGFR and HER3 CTT-only constructs in a bacterial Escherichia coli 
system. EGFR residues 961–1186 with a C-terminal His tag were purified using nickel-
nitrilotriacetic acid column chromatography and gel filtration. Estimated purity by SDS-PAGE 
was 95% (figure 2.2.A) with a concentration of 5 mg/ml. The HER3 CTT, HER3 residues 981–
1342, was also expressed in E. coli and purified to a concentration of 2 mg/ml with 95% purity in 
the same manner (figure 2.2.B).  
Confirmation of EGFR C-terminal Tail Function 
Phosphorylation of the CTT region and subsequent binding of SH2 domain-containing proteins 
are essential steps in EGFR signaling. We first validated the ability of our CTT constructs to be 
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both recognized and phosphorylated at specific tyrosine sites by separate EGFR family kinase 
domains in solution just as they would be if they were part of their respective ICH constructs. To 
test whether the E. coli-expressed EGFR CTT construct is functional, we incubated it with 
recombinant EGFR kinase domain and measured tail phosphorylation using reaction with ATP 
and blotting with phosphospecific antibodies. We show, through Western blotting identification 
of specific phosphorylated tyrosine residues (EGFR Tyr-1068 and Tyr-1173) in the EGFR CTT 
(figure 2.2.C), that the EGFR CTT is recognized and phosphorylated by the EGFR kinase 
domain even when these two domains are expressed as separated constructs. Further- more, we 
used anti-HER3 Tyr(P)-1289 and general PY20 anti- bodies to verify that the HER3 CTT was 
phosphorylated by both the EGFR kinase domain and HER2 kinase domain via Western blotting 
(figure 2.2.D). Next, we tested whether EGFR CTT can be bound by an SH2 domain-containing 
protein. We recombinantly expressed GST-tagged Grb2 SH2 domain and performed a GST 
pulldown assay (figure 2.2.E). Incubating EGFR CTT with EGFR kinase domain produced a 
phosphorylated CTT that appeared as multiple bands of higher molecular weight, and this 
phosphorylated EGFR CTT did not bind on its own to glutathione-agarose (figure 2.2E, flow-
through in lane 1 and bound in lane 2). Similarly, incubating unphosphorylated EGFR CTT with 
the GST-Grb2 SH2 domain construct did not result in binding, and EGFR CTT eluted in the 
flow-through (lane 3). However, once phosphorylated, EGFR CTT was bound by GST-Grb2-
SH2 and was pulled down by glutathione-agarose (figure 2.2.E, lane 6). These experiments 
provide evidence for the functionality of the EGFR and HER3 CTT constructs.  
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Figure 2.2. Purification and Phosphorylation of C-Terminal Tail (CTT) constructs. A, 
Coomassie stained SDS-PAGE gel of EGFR CTT purification. Lanes 1 and 4 are molecular 
weight markers, labeled respectively. Lane 2 is transformed cell lysate pre-induction with IPTG. 
Lane 3 is lysate post-induction. Lane 5 is purified EGFR CTT following Ni2+ chelating 
chromatography and gel filtration. EGFR CTT purity determined to be >95%. B, Coomassie 
stained SDS-PAGE gel of HER3 CTT purification. This gel uses similar lane arrangement as in 
figure 2.2.A for HER3 CTT expression. C, EGFR CTT is recognized and phosphorylated by the 
EGFR kinase domain. Phospho-specific antibodies to EGFR pY1068 and EGFR pY1173 were 
used to detect CTT phosphorylation. D, Western blot analysis of HER3 CTT phosphorylation. 
The HER3 ICH serves as a positive control showing C-terminal tail phosphorylation via 
interaction with EGFR KD or HER2 KD. HER3 CTT is recognized and phosphorylated by the 
EGFR and HER2 kinase domains, just as it would be as if it was part of its ICH construct. 
Phospho-specific antibodies to HER3 pY1289 and general anti-phosphotyrosine pY20 were used 
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to detect HER3 CTT phosphorylation. E, Phosphorylated EGFR CTT binds to the Grb2-SH2 
domain. GSH-agarose beads were pre-loaded with GST tagged Grb2-SH2 domain protein. 
Phosphorylated or unphosphorylated EGFR CTT was then incubated with the beads for 2 hours 
at 4 °C, flow-through (FL) collected, washed, then the beads were boiled in sample buffer 
(Bound). SDS-PAGE of fractions then transferred to Nitrocellulose. Anti His6-HRP Ab was used 
to detect EGFR CTT in the FL and bound fractions. 
 
Analysis of EGFR CTT by CD Spectroscopy 
Far-UV CD spectroscopy provides information about the secondary structure characteristics of 
protein molecules in solution based on the absorption of circularly polarized light by amide 
bonds in the polypeptide backbone. Because secondary structure types absorb circularly 
polarized light differently and each amide bond contributes to the UV absorption, the resulting 
spectrum will reflect a global average of the secondary structure content in a protein. Due to a 
lack of -helix and -sheet content, mostly or fully disordered and unfolded proteins will have CD 
spectra that are distinct from highly ordered proteins. The CD spectra between 190 and 260 nm 
wavelengths for EGFR CTT and HER3 CTT are shown in figure 2.3, A and B, respectively. 
Distinctive features expected for a mostly -strand protein would include a positive ellipticity 
maximum at 195nm with a negative ellipticity minimum near 215 nm. For a mostly -helical 
protein, one would expect two minima, one at 208 nm and the other at 224 nm wavelength, along 
with a pronounced maximum near 192nm (55, 93). However, the CD spectrum observed for 
EGFR CTT shows a minimum between 195 and 200 nm, which is a characteristic of disordered 
proteins (figure 2.3.A). However, the slightly negative ellipticity at 222nm indicates the 
possibility of residual secondary structure. Analysis via the CDSSTR algorithm, an algorithm 
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used to assign secondary structure composition to CD spectra, shows 77% unordered character in 
the EGFR CTT spectrum (figure 2.3.C). These results suggest that much of the EGFR CTT 
construct has an unfolded conformation in solution. The CD spectrum for HER3 CTT shows 
similar features as the EGFR CTT with a minimum between 195 and 200 nm and slightly 
negative ellipticity at 222 nm (figure 2.3.B). The HER3 CTT has mostly unordered content 
(60%) but slightly higher β-sheet content than EGFR CTT: regular -strand (R) 15% and 
distorted -strand (D) 7% for HER3 CTT as compared with R  6% and D 3% for EGFR CTT 
(figure 2.3.C). 
Figure 2.3. Circular dichroism spectroscopy. A, The CD spectrum for the EGFR CTT 
construct does not show prominent spectral features of α-helices and β-sheets. B, Similarly, the 
HER3 CTT CD spectrum shows high unordered content, with slightly higher calculated β-sheet 
content than in the EGFR CTT spectrum. C, Secondary structure assignment was assigned the 
following symbols: regular α-helix (αR), distorted α-helix (αD), regular β-strand (βR), distorted 
β-strand (βD), turns (T), and unordered (U). 
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Size Exclusion Chromatography with Multiangle Light Scattering 
Another property of intrinsically disordered regions is a higher than expected apparent molecular 
mass during gel filtration separations (59). SEC can be used to separate proteins based on their 
hydrodynamic size, which is increased in IDRs depending on the degree of conformational 
extension. Proteins with higher hydrodynamic size elute earlier than smaller proteins, and 
accurate, absolute measurement of molecular weight can be obtained by coupling SEC to a 
MALS detector (60). Figure 2.4.A shows the SEC elution chromatograms for both the EGFR 
CTT and carbonic anhydrase with the coupled MALS detection inserted above. Our analysis 
shows that EGFR CTT and carbonic anhydrase share similar molecular masses at 26 and 29kDa, 
respectively, and both are monomeric under these conditions. EGFR CTT elutes from the SEC 
column before 13 ml of buffer volume. Despite having a lower molecular weight, the EGFR 
CTT elutes earlier than carbonic anhydrase, which elutes just after 15 ml of buffer. The expected 
Stokes radius of carbonic anhydrase is 2.4 nm (107). This earlier elution indicates that the EGFR 
CTT conformational ensemble is more extended than that of carbonic anhydrase, which has a 
globular structure. Figure 2.4.B shows the SEC-MALS chromatogram profiles for HER3 CTT 
and EGFR kinase domain. The molecular masses, determined by MALS, of the HER CTT and 
EGFR kinase domain were 42 and 38 kDa, respectively. HER3 CTT eluted at about 14 ml of 
buffer, which is earlier than the EGFR kinase domain, which eluted between 16 and 17 ml of 
buffer. As with EGFR CTT, no multimeric peaks were observed in the HER3 CTT 
chromatogram.  
Dynamic Light Scattering 
The DLS technique is used to analyze hydrodynamic properties of proteins in solution. Using the 
hydrodynamic radius, or Stokes radius, derived from measurements of translational diffusion 
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coefficients, we are able to differentiate between a protein ensemble with mostly compact, 
globular conformations and one with more extended conformations as would be seen for IDRs 
(61). DLS is complementary to the static light scattering used in SEC-MALS in that DLS 
provides information on molecular size, whereas MALS provides a molecular weight and 
verification of a monomeric state. A histogram showing a distribution of measured 
hydrodynamic radii within the EGFR CTT and bovine serum albumin (BSA) populations is 
shown in figure 2.4.C. The EGFR CTT, which has a molecular mass of 26kDa, was determined 
to have a hydrodynamic radius of 5.3 nm. For a comparison, we also analyzed BSA, a globular 
protein with a molecular mass of 66 kDa, and the hydrodynamic radius of BSA was measured to 
be 4.8 nm. This demonstrates that EGFR CTT has a larger hydrodynamic radius than a globular 
protein more than 2.5 times its size. Similarly, HER3 CTT has a very large hydrodynamic radius 
(figure 2.4.D). The hydrodynamic radius (RH) of HER3 CTT is 6.4 nm, although it has higher 
polydispersity than EGFR CTT.  
Analytical Ultracentrifugation 
We used sedimentation velocity AUC to determine the sedimentation coefficient, s, of EGFR 
CTT, which provides information about the molecular weight of the tail, Mf, as it relates to its 
RH (figure 2.4.E). We also determined that our sample is homogenous due to the absence of 
secondary peaks in figure 2.4C as secondary populations or impurities would have different 
sedimentation velocities. From these AUC measurements, we obtained the frictional coefficient 
of the tail, f, which can be used to relate its molecular shape to that of a globular protein. The 
frictional ratio, f/fmin, provides an indication of the shape of a macromolecule based on the ratio 
of its measured frictional coefficient to a theoretical minimum frictional coefficient for a particle 
with minimum Stokes radius at a given molar mass (62). For a globular protein, the expected 
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f/fminwouldfallbetween1.15and1.3 (108-110). We determined the f/fmin value for EGFR CTT to 
be much greater, at 1.77, which is consistent with this being an IDR. Similarly, HER3 CTT has 
an f/fmin value of 1.52, which is also greater than the expected frictional ratio for globular 
proteins (figure 2.4F).  
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Figure 2.4 Hydrodynamic Properties of EGFR CTT. A, Elution chromatograms and molecule 
weight determination of EGFR CTT by SEC-MALS. EGFR CTT data is shown in red, carbonic 
anhydrase data is shown in blue. Despite similar molecular weights, EGFR CTT elutes sooner, 
indicating a larger hydrodynamic size. B, SEC-MALS analysis of HER3 CTT. HER3 CTT data 
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is shown in red, EGFR kinase domain data is shown in blue. Again, the two molecules share 
similar molecular weights, but HER3 CTT elutes sooner than the EGFR KD. C, Hydrodynamic 
radius determination of the EGFR CTT and BSA by dynamic light scattering. The measured 
DLS hydrodynamic radius distribution for EGFR CTT is shown as yellow bars. The measured 
hydrodynamic radius of EGFR CTT is 5.3 nm. The histogram for BSA (monomeric fraction 
obtained by gel-filtration) is shown as red bars. The RH of monomeric BSA is 4.8 nm. D, 
Hydrodynamic radius determination of the HER3 CTT. The measured DLS hydrodynamic radius 
for HER3 CTT is 6.4 nm. E, Frictional coefficient, frictional ratio, and molecular weight 
determined by analytical ultracentrifugation. Sedimentation coefficient is used to measure an 
apparent molecular weight of Mf = 23.5 kDa. The frictional ratio for the EGFR CTT is 1.77, 
indicating a large Stokes radius relative to globular proteins. F, Frictional coefficient, frictional 
ratio, and molecular weight determined by analytical ultracentrifugation. The measured apparent 
molecular weight of HER3CTT is 31.6 kDa. The frictional ratio is 1.52. 
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Small Angle X-ray Scattering 
Small angle X-ray scattering methods have been particularly useful in analyzing conformation 
ensemble properties of IDRs (63). In small angle X-ray scattering analyses, we measured the 
isotropic scattering intensity, I(s), as a function of the momentum transfer, s, of monochromatic 
X-ray light diffracted by protein macromolecules in solution. In protein structure studies, SAXS 
has been used to characterize structure and dynamics of monodisperse molecular species with a 
dominating structural configuration. IDRs show larger average sizes compared with globular 
proteins that contain tightly packed cores. By comparing the measured R
g and Dmax from SAXS 
with other known structured globular proteins, together with Kratky plots (I(s)s
2 as a function of 
s), which characterizes the flexibility state of the proteins, one is able to identify the flexibility of 
the IDRs (111). Figure 2.5.A shows the scattering profiles for EGFR CTT and BSA. In figure 
2.5.B, Guinier plot regions of EGFR CTT in three different concentrations are shown. R
g values 
calculated by AutoRg (101) are 46.6  2.2 (EGFR CTT) and 33.6  0.6 Å (BSA), and the 
molecular masses for each of them are 25.6  0.7 and 69.0  2.0 kDa, respectively (Table 2.2.). 
The Kratky plot (figure 2.5.C) of BSA shows a parabolic shape with a well-defined peak. In 
contrast, EGFR CTT shows a hyperbolic shape on the Kratky plot, indicating an intrinsically 
disordered region (figure 2.5.C). Figure 2.5D shows the pair distribution function (P(r)) of 
EGFR CTT generated by Datgnom (100). The Dmax of EGFR CTT is 156  6 Å, which is much 
larger than that of BSA (Table 2.2.). Thus, the Rg and Dmax measurements, Kratky plot, and 
P(r) distribution of EGFR CTT indicate that the conformational ensemble adopted by EGFR 
CTT is extended and flexible. When we analyzed the HER3 CTT with SAXS, we also included 
samples containing urea to determine whether a chemical denaturant would have an effect on the 
conformational ensemble. It is also important to note that, unlike in EGFR CTT buffer, 5% 
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glycerol was also included in the HER3 CTT buffer. The glycerol was necessary to maintain 
protein solubility and stability of the HER3 CTT, but it may also act to stabilize conformations 
with diminished extendedness. We do not directly compare derived Rg values between EGFR 
CTT and HER3 CTT because of this difference in buffer conditions. The scattering profiles for 
HER3 CTT without urea and with 4 M urea are shown in figure 2.6A, and Guinier plot regions 
are shown in figure 2.6B. From these data, we calculated an Rg of 45.4  0.4 Å in the absence of 
urea, and that increases slightly to 50.5  1.2 Å upon the addition of 4M urea (Table 2.2.). The 
derived Kratky profiles for these two conditions are shown in figure 2.6.C. Without urea present, 
the HER3 CTT produces a slightly parabolic Kratky profile, with a defined local maximum 
observed, at lower momentum transfer values. Moving toward greater momentum transfer values 
then gives a more hyperbolic increase in I(s)s
2
. For HER3 CTT with 4 M urea, the Kratky profile 
has a hyperbolic shape indicative of disorder, similar to the profile observed for the EGFR CTT 
(figure 2.5.C). The difference in Kratky plots between HER3 CTT with or without urea, together 
with increased Rg, indicates that HER3 CTT possesses characteristics of IDRs but not of random 
coil structures when in solution.  
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Figure 2.5. Small angle X-ray scattering analysis of EGFR CTT. A, Scattering profiles of 
EGFR CTT (red) and BSA (blue). B, Guinier plots of EGFR CTT in different concentrations, 
0.9, 1.8, and 3.7 mg/ml. C, The data is represented in a Kratky Plot with arbitrary units. In folded 
proteins like BSA (blue), Kratky plot shows parabolic features. While in the EGFR CTT Kratky 
plot (red), a hyperbolic shape indicates intrinsically disordered protein character. D, Pair 
distribution functions for the EGFR CTT (red) and BSA (blue) scattering profiles, generated 
using Datgnom (55). 
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Figure 2.6 Small angle X-ray scattering analysis of HER3 CTT in solution ± urea. A, 
Scattering profiles of HER3 CTT in solution without urea (blue) and with 4M urea (red). B, 
Guinier plots of HER3 CTT with or without the presence of 4 M urea. C, The data is represented 
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in a Kratky Plot with arbitrary units. The Kratky Plot for HER3 CTT with 4M urea additive 
shows a more hyperbolic profile, indicating greater disorder with the addition of chemical 
denaturant. 
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Table 2.2. Structural parameters observed by SAXS. 
a
 Values were calculated based on protein amino acid sequences. 
b
 Measured MW was calculated from the X-ray scattering profile. 
c
 Buffer for EGFR CTT was 20mM Phosphate pH 8.0, 150mM NaCl 
d
 Buffer for Her3 CTT was 20mM Tris-HCl pH 8.0, 300mM NaCl, 5% glycerol, +/- 4M Urea as indicated 
above. 
e
 Values of EGFR kinase domain were calculated from a theoretical scattering profile generated by the 
Crysol program using the crystal structure of EGFR kinase domain (PDB accession number 1XKK). 
f
 Characteristics of intrinsically disordered proteins are shown in the Kratky plots for these constructs. 
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2.6 DISCUSSION  
We have shown that the CTT domains in EGFR family proteins are intrinsically disordered 
regions that have an extended, highly dynamic conformational state. CD spectroscopy shows that 
they have high unordered character as expected for IDRs. SEC and DLS demonstrate that 
hydrodynamic size of the CTT is larger than protein standards of comparable molecular weight, 
which is another property of IDRs. AUC and the Kratky plot from SAXS demonstrate that the 
CTTs are IDRs, and Rg and Dmax measurements from SAXS demonstrate that the CTTs have an 
extended conformation. The Rg and Dmax measurements of the EGFR kinase domain were 
estimated from crystal structure (Protein Data Bank code 1XKK), and we observed that the 
EGFR CTT had Rg and Dmax values that were 2.4 times larger than those of the EGFR kinase 
domain. A striking finding on the EGFR and HER3 CTTs is that despite their low primary 
sequence homology (22% sequence identity) the structural features of the CTTs are strongly 
conserved. This implies that the intrinsic disorder of these tails is important for their function, 
and the multiple conformers that a disordered region can adopt could reduce the thermodynamic 
barriers for protein binding and thereby increase both the on- and off-rates for binding of SH2 
domain-containing proteins. Furthermore, the extended conformation of the CTT could increase 
the capture radius for recruitment of these signaling proteins (112, 113). Both mechanisms would 
facilitate signal propagation by these receptor tyrosine kinases. The intrinsically disordered 
properties of these CTTs also explain why these regions are mostly absent from crystallographic 
studies on EGFR (47, 82). In conclusion, these methods demonstrate that the EGFR and HER3 
CTTs are IDRs with extended, non-globular structure in solution, and this finding may have 
important implications for the recruitment of downstream signaling proteins and signal 
propagation from these RTKs.  
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Chapter 3: Efficient sortase-mediated N-terminal labeling of TEV 
protease cleaved recombinant proteins  
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This chapter was adapted from: 
Sarpong K, Bose R. (2017) Efficient Sortase-mediated N-terminal Labeling of TEV 
Protease Cleaved Recombinant Proteins. Anal. Biochem. 15, 55 – 58.  
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3.2 ABSTRACT 
A major challenge in attaching fluorophores or other handles to proteins is the availability of a 
site-specific labeling strategy that provides stoichiometric modification without compromising 
protein integrity. We developed a simple approach that combines TEV protease cleavage, sortase 
modification and affinity purification to N-terminally label proteins. To achieve 
stoichiometrically-labeled protein, we included a short affinity tag in the fluorophore-containing 
peptide for post-labeling purification of the modified protein. This strategy can be easily applied 
to any recombinant protein with a TEV site and we demonstrate this on Epidermal Growth 
Factor Receptor (EGFR) and Membrane Scaffold Protein (MSP) constructs. 
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3.3 INTRODUCTION 
Site-specific protein labeling is the method of choice for most biochemical and 
biophysical applications, as this offers a high level of precision for the attachment of a 
fluorophore or other chemical moiety (69, 70). Due to the relatively low abundance of cysteines 
in proteins (71), chemical labeling of proteins using maleimide chemistry is a common strategy 
for most applications.  However, many proteins contain multiple cysteine residues and 
mutagenesis of these cysteines is time-consuming and may compromise protein function. An 
alternate approach is to label primary amines with N-hydroxysuccinimide ester-based 
fluorophores. However, the relatively high abundance of lysines and pKa requirements renders 
the utility of amino groups for protein modification a less commonly used strategy. These 
challenges are compounded by long reaction times to ensure complete modification of the 
protein. With fluorophores having a MW of <1kDa, separation of labeled products from the 
unlabeled protein can also present challenges. Sub-stoichiometric labeling often results in a 
diminished signal-to-noise ratio and impacts the utility of fluorophore-labeled proteins for 
biophysical studies. 
Enzymatic approaches for site-specific incorporation of fluorophores are an alternative to 
these chemical labeling strategies. Sortases are membrane-associated transpeptidases that anchor 
Gram-positive bacterial surface proteins to their cell walls. Since the discovery of sortases, 
Staphylococcus aureus sortase A (SrtA) has been the prototype for understanding the mechanism 
of action of these enzymes (73). Proteins anchored to the bacterial cell wall by SrtA possess a C-
terminal sorting signal that contains a hydrophobic domain sandwiched between the conserved 
LPXTG recognition motif and a positively charged tail (73). SrtA catalyzes the hydrolysis of the 
peptide bond between the threonine and glycine residues to generate an acyl-enzyme 
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intermediate that is subsequently attacked by an oligoglycine peptide in a nucleophilic attack 
(74). This results in the formation of a new peptide bond between the incoming nucleophilic 
glycine-containing peptide and the protein. Seminal work (by Schneewind and coworkers) that 
laid the ground for its utility in biochemical and biotechnological studies showed a recombinant 
peptide containing the LPXTG motif alone is sufficient for recognition and catalysis (75). These 
studies also indicated that a peptide containing 1-3 N-terminal glycines could replace the 
peptidoglycan involved in the sortase-mediated reaction (75). Current biochemical evidence has 
suggested that only one additional residue (preferably a glycine) is required at the C-terminus of 
the LPXTG recognition sequence for efficient sortase binding and catalysis (76). 
Most recombinant proteins used for biochemical and biotechnological applications 
contain affinity tags that ensure their easy and efficient purification (114, 115). Sandwiched 
between the affinity tags and the proteins are protease recognition sites that offer the cleavage of 
the affinity tags following purification. Commonly used recognition sites include TEV, Factor 
Xa, and Thrombin protease cleavage sites. An important requirement for the sortase reaction is 
the generation of the N-terminal glycine residue which can be done by removing the initial 
methionine of an expressed protein using methionylaminopeptidase or engineering a thrombin or 
TEV protease recognition site that exposes an N-terminal glycine following cleavage (116). 
Recent years have seen the development and utility of sortase to modify proteins at their 
carboxyl and amino termini in addition to internal loops (76, 77). Unlike traditional chemical 
strategies that are easy to use, protein modification employing short genetically encoded tags 
such as the LPXTG-tag, ACP-tag and LAP-tag offer a high degree of precision. However, back 
reaction from the final product (containing the LPXTG motif and therefore an efficient substrate 
for the sortase enzyme) and the reversible nature of the sortase reaction can lead to sub-
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stoichiometric protein modification and decreased labeling efficiencies. To address this 
challenge, the equilibrium of the reaction is driven towards product formation by increasing the 
fold excess of the fluorophore-containing peptide (76, 77). Recent methodologies to address this 
issue of irreversibility have included the use of a sortase-tagged expressed protein ligation 
(STEPL) system that circumvents the removal of unconjugated species (117), dialysis to remove 
reaction by-products (118) and the introduction of tryptophan-derived zippers around the SrtA 
recognition motif that induces the formation of a stable β-hairpin (119). Other research groups 
have solved this problem by utilizing a depsipeptide, which replaces the amide bond between the 
threonine and glycine residues with an ester linkage (120). These challenges make protein 
modification using sortase cumbersome and potentially expensive when the fluorophore-
containing peptide is needed in many fold excess. The presence of reaction by-products as a 
result of back reaction and the reversible nature of the reaction affect the purity and degree of 
labeling of the final product, and subsequently present challenges in the utilization of 
fluorophore-labeled proteins. 
We have developed a simple approach that combines TEV protease cleavage, sortase 
modification and affinity purification to N-terminally label proteins. To achieve 
stoichiometrically-labeled product, a short affinity tag is included in the fluorophore-containing 
peptide so that post-labeling affinity purification of only the labeled protein can be performed. 
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3.4 METHODS 
Plasmids 
Staphylococcus aureus sortase A plasmid was generously provided by the Ploegh lab (MIT). 
This sortase A pentamutant (SrtA 5M) is Ca
2+
 -dependent and had previously undergone directed 
evolution to be catalytically more efficient (121). SrtA 5M contains five mutations and has a 
140-fold increase in transpeptidase activity over wildtype SrtA. We engineered SrtA 5M to have 
a TEV cleavage site before the C-terminal histidine tag, to facilitate our downstream purification 
strategy. Sequences of all the plasmids were confirmed by DNA sequencing. 
Expression, purification and TEV protease cleavage of EGFR kinase domain constructs:  
We expressed and purified the EGFR kinase domain using a protein expression protocol 
described previously (4, 36). Recombinant bacmid (Bac-to-Bac expression system, Gibco BRL) 
was transfected into Spodoptera frugiperda Sf9 cells to produce recombinant baculovirus, which 
were used to infect Sf9 cells grown at 27 °C and 120 rpm in IPL-41 medium (Invitrogen) 
supplemented with 10% bovine calf serum supplemented (Hyclone), yeastolate extract 
(Invitrogen), penicillin, streptomycin, and Pluronic F-68. Cultures at a density of 1 x 10
6 
cells/ml 
were infected at 1 MOI and cells were harvested 48 – 72hours post infection by centrifugation at 
6000 rpm and resuspended in Buffer A (25 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM 
imidazole, 5% glycerol, 1 mM DTT) supplemented with phenylmethylsulfonyl fluoride, 
benzamidine, DNase, and protease inhibitor mixture tablets lacking EDTA (Roche). The cells 
were homogenized using a probe sonicator and the lysate was centrifuged at 20000 rpm for 45 
mins. 0.5 - 0.75 ml of Ni-NTA beads (Qiagen) were added to the supernatants and incubated on a 
rotator for 1 h at 4 °C. The beads were poured into a 10-ml disposable column (Bio-Rad) and the 
flow-through collected. The column was washed with 10 column volumes of Buffer A + 20 mM 
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imidazole, and the proteins were eluted with Buffer A + 50–125 mM imidazole. The eluted 
fractions were further purified by gel filtration chromatography on a Superdex 200 GL 10/300 
column (GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer. 
Pooled fractions were concentrated and treated with TEV protease (at a mass ratio of 1mg of 
TEV protease to 40mg of EGFR kinase domain) overnight at 4C to remove the N-terminal His-
tag and generate an EGFR kinase domain with an N-terminal glycine, Gly-EGFR. This was 
bound to Ni-NTA beads and the flow-through was concentrated, snap frozen, and then stored 80 
°C. We also expressed and purified two other EGFR kinase domain constructs, whose TEV 
cleavage resulted in two and four N-terminal glycines, Gly2-EGFR and Gly4-EGFR respectively. 
Expression, purification and TEV protease cleavage of Sortase A protein constructs 
The protocol we used for expressing and purifying SrtA 5M (with and without the TEV cleavage 
site) had been previously described (76). Briefly, BL21 (DE3) competent E. coli cells were 
transformed with pET30b S. aureus sortase A 5M or pET30b S. aureus sortase A 5M (containing 
an insertion for TEV protease cleavage) onto LB-kanamycin plates. An individual colony was 
picked and inoculated into 100 mL LB-ampicillin and placed in a shaker at 220 rpm at 37 °C 
overnight. 10 mL of the overnight culture was diluted into 1 L LB media with the corresponding 
kanamycin. This was grown at 37°C until OD600 of 0.4–0.6 (~3 h) was achieved. Expression was 
induced through the addition of 0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG) for 16 h at 
25 °C. The bacterial cells were centrifuged at 6,000 x g for 15 min at 4 °C. The pellet was 
resuspended in 50 ml Nickel-binding buffer (50 mM Tris-HCl, pH 7.5 and 150 Mm NaCl), 
transferred to a 50 ml centrifuge tube, centrifuged again and the pellet frozen at −80 °C. Cell 
lysis was performed at 4 °C with a probe sonicator on frozen pellets using 25 ml ice cold lysis 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 mM imidazole, 10% (vol/vol) 
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glycerol, 1 mg ml−1 DNase and 1 mg ml−1 lysozyme). The lysate was clarified by 
centrifugation at 20,000 x g for 30 min at 4 °C. A Poly-prep column was packed with 1–1.5 mL 
(bed volume) nickel-nitrilotriacetic acid (Ni-NTA) agarose resin and washed with 10 column 
volumes of wash buffer (by gravity flow) and the bacterial supernatant loaded onto the column 
(by gravity flow). The column was then washed with 50 column volumes of wash buffer to 
remove nonspecifically bound proteins and proteins eluted with 3 column volumes ice-cold 
elution buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 500 mM imidazole and 10% (vol/vol) 
glycerol). The protein was buffer exchanged and concentrated to 15 mg/ml in Nickel-binding 
buffer (no imidazole) + 10% imidazole. A fraction was aliquoted into tubes, snap frozen in liquid 
N
2 and stored at -80 °C. The SrtA 5M construct containing a TEV cleavage site was treated with 
TEV protease (at a mass ratio of 1mg of TEV protease to 40mg of SrtA) overnight at 4C to 
remove the N-terminal His-tag. This was bound to Ni-NTA beads and the flow-through was 
concentrated, snap frozen, and then stored 80 °C. Protein concentration was determined using 
UV-visible spectroscopy with a molar extinction coefficient of SrtA 5M (with a TEV cleavage 
site) at 280nm of  = 15,930.  
Enzymatic activity of SrtA 5M constructs 
 
The sortase activity of the wildtype SrtA 5M and SrtA 5M containing a TEV cleavage site was 
determined using an already published protocol (122). We used a self-fluorescent quenching 
peptide, o-aminobenzoyl-LPETG-2,4-dinitrophenyl as a substrate in the cleavage reaction 
containing 1.5 M SrtA enzyme dissolved in assay buffer (20 mM HEPES, pH 7.5, 10mM 
CaCl2). The o-aminobenzoyl-LPETG-2,4-dinitrophenyl substrate was dissolved in dimethyl 
sulfoxide and added to the reaction to a final concentration of 6.25 M, for a total reaction 
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volume of 37.5 l. The samples were incubated at 37 C for 1 hr and analyzed in a 
spectrophotometer using 340 nm for excitation and recording the emission maximum at 420 nm.  
Design and fluorophore-labeling of peptides 
The LPETGG sortase substrate was made using solid-phase synthesis on a Wang resin. 
Following removal of the Fmoc on the -aminocaproic acid residue, 3 molar equivalents of 5(6)-
TAMRA succinimidyl ester was added and the column wrapped in aluminum foil. This was 
shaken overnight at room temperature. The resin was cleaved in a solution consisting of 95 % 
TFA, H2O and TIS, and the final crude TAMRA-LPETGG was purified by reversed-phase 
HPLC on a C18 column using a 10 – 70 % Buffer B (H2O, Acetonitrile and 0.05% TFA) 
gradient over 15 mins. The fractions were analyzed by LC/MS and the desired fractions were 
pooled together and lyophilized to dryness. We also designed a 25-mer peptide, 
MSYYHHHHHHDYDIPTCENLPETGG (or H6-LPETGG peptide, hereafter) that was labeled 
with fluorescein (or CruzQuencher) at the N-terminus using the same protocol described for 
labeling with TAMRA. For labeling of the H6-LPETGG peptide at the internal cysteine residue, 
the lyophilized peptide was reconstituted into water and the pH adjusted to around 8. Three 
molar equivalents of fluorescein (in DMSO) was added to 5mg of peptide in 50 mM Tris-HCl, 
pH 7.3 and 150 mM NaCl, and incubated at room temperature overnight. The labeled peptide 
was purified, analyzed and lyophilized using the method described above. Measurement of the 
absorbance of the peptide and fluorophore at 280 nm (A280 and Amax, respectively) and their 
molar extinction coefficients (εprotein and εmax, respectively), allowed us to calculate the peptide 
concentration and degree of labeling using equation 1 below; 
  
𝐷𝑂𝐿 =  
𝐴𝑚𝑎𝑥 ∙ 𝜀𝑝𝑒𝑝𝑡𝑖𝑑𝑒
(𝐴280 −  𝐴𝑚𝑎𝑥  ∙  𝐶𝐹280) ∙ 𝜀𝑚𝑎𝑥
 
58 
 
 
The correction factor (CF) is included in this equation to account for the absorption of 
fluorophore at 280 nm and equals the A280 of the dye divided by the Amax of the dye. 
TAMRA-LPETGG labeling of Gly-EGFR, Gly2-EGFR and Gly4-EGFR 
0.5 mM of TAMRA-LPETGG was mixed with 25 M of either Gly-EGFR, Gly2-EGFR or Gly4-
EGFR and 1 M SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 10 
mM CaCl2. The reaction was incubated at 4 C with shaking and aliquots taken at 1 min, 5 mins, 
15 mins, 30 mins and 1 hr. These, together with their unlabeled counterparts, were boiled in 
SDS-gel loading buffer for 2 mins and analyzed by SDS-PAGE.  
Quenching of sortase activity by EDTA and EGTA 
1.5 M of SrtA 5M was added to a reaction containing 6.25 M of o-aminobenzoyl-LPETG-2,4-
dinitrophenyl in 20 mM HEPES, pH 7.5, 10mM CaCl2, in the presence and absence of 10 and 20 
M of EDTA or EGTA. The samples were incubated at 37 C for 1 hr and analyzed in a 
spectrophotometer using 340 nm for excitation and recording the emission maximum at 420 nm. 
Sortase-mediated labeling and purification of EGFR kinase domain 
In our newly developed strategy for labeling EGFR kinase domain with a fluorophore using 
sortase (Figure 3.1) , 0.5 mM of CruzQuencher-labeled H6-LPETGG peptide was mixed with 25 
M of Gly-EGFR and 1 M SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, and 10 mM CaCl2. The reaction was incubated at 4 C for 30 mins and quenched with 10 
mM EDTA. This was loaded onto a Superdex 75 10/30 GL column (GE Healthcare Life 
Sciences, Pittsburg, PA) and pooled fractions containing the EGFR kinase domain was incubated 
with 200 l of Nickel NTA beads at 4 C for 30 mins. CruzQuencher-labeled EGFR was eluted 
with 125 mM imidazole, buffer exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM 
59 
 
NaCl, 1 mM DTT) and concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the 
process and analyzed by SDS-PAGE. We determined the concentration and degree of labeling of 
the CruzQuencher-labeled EGFR using equation 1, where peptide is replaced with protein in the 
equation.  
 
Figure 3.1. Schematic representation of N-terminal labeling of TEV-cleavable proteins 
using sortase. Green circle at the N-terminus of peptide indicates the fluorophore or any other 
desired moiety. Affinity tag used in here was 6x-His. However, this tag can be varied and the 
purification process can be made more stringent by using two different affinity tags. As noted in 
the text, the TEV recognition motif used must be ENLYFQG rather than ENLYFQS. 
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Sortase-mediated labeling and purification of MSP1E3D1 protein 
MSP1E3D1 protein was treated with TEV protease to generate Gly- MSP1E3D1. 0.5 mM of 
fluorescein-labeled H6-LPETGG peptide was mixed with 25 M of Gly- MSP1E3D1 and 1 M 
SrtA 5M in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 10 mM CaCl2. The 
reaction was incubated at 4 C for 30 mins and quenched with 10 mM EDTA. This was loaded 
onto a Superdex 75 10/30 GL column (GE Healthcare Life Sciences, Pittsburg, PA) and pooled 
fractions containing the MSP1E3D1 protein were incubated with 200 l of Nickel NTA beads at 
4 C for 30 mins. Fluorescein-labeled MSP1E3D1 was eluted with 125 mM imidazole, buffer 
exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) and 
concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the process and analyzed by SDS-
PAGE. We determined the concentration and degree of labeling of the fluorescein-labeled 
MSP1E3D1 using equation 1, where peptide is replaced with protein in the equation.  
Kinase activity of labeled EGFR kinase domain 
The protocol used to measure the kinase activities of labeled EGFR kinase domains, both in 
solution and on Nickel liposomes (to induce dimerization) have been described in Ref. 36. 
Wildtype or fluorophore-labeled EGFR kinase domain were incubated in 20 mM Tris, pH 7.5, 10 
mM MgCl2, 100 M Na3VO4, 2 mM DTT, 100 M ATP, 1 Ci of [- 32P] ATP, 60 mM NaCl, 
5% glycerol in 25-l total reaction volume. The reaction was initiated by the addition of 1.25 M 
kinase, incubated at 30 C for 6 mins and quenched with EDTA. 100 g of avidin was added to 
the samples and transferred to centrifugal filtration units with 30,000 molecular weight cutoff 
(Millipore). The samples were washed four times with 0.5 M sodium phosphate, 0.5 M NaCl, pH 
8.5 and the retained 
32
P measured by scintillation counting. The kinase activity on liposomes was 
measured by incubating the wildtype and fluorophore-labeled EGFR kinase domains with nickel 
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liposomes on ice for 15 mins before initiating the reaction. Total lipid concentration was 0.5 
mg/ml. 
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3.5 RESULTS 
Expression and TEV protease cleavage of EGFR kinase domain constructs 
The Sf9 insect cell baculovirus system was used to express all EGFR kinase domain (residues 
constructs. Our two-step purification strategy (Nickel NTA chromatography and Gel filtration) 
resulted in >95% purity and ~60% yield. Following overnight incubation with TEV protease, we 
performed a reverse Nickel NTA purification by binding the TEV protease and uncleaved EGFR 
kinase domain to the Nickel beads. The flow through containing the TEV protease-cleaved 
EGFR kinase domain was concentrated, resulting in >95% purity and ~30% yield (figure 3.2). 
Time-dependent incubation of EGFR kinase domain with TEV protease allowed the shortening 
of the incubation period from 16hours to less than 8 hours and still preserves the activity of the 
EGFR kinase. 
 
 
Figure 3.2. Coomassie-stained SDS-PAGE gel of EGFR kinase domain purification and 
TEV protease cleavage.  
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Expression and enzymatic activity of Sortase A 5M (with no His-tag) 
Bacterial expression of Sortase A 5M (with and without His-tag) produced milligram amounts of 
the proteins, which were purified using a one-step Nickel NTA chromatography. The protein 
yield was 75% while SDS-PAGE analysis showed a >95% purity of the TEV protease-cleaved 
Sortase A 5M (figure 3.3). Enzymatic activity assays using o-aminobenzoyl-LPETG-2,4-
dinitrophenyl as a substrate showed that Sortase A 5M (without a His-tag) had comparable 
sortase activity to the wildtype Sortase A 5M, as showed in Figure 3.4. 
 
Figure 3.3. Coomassie-stained SDS-PAGE gel of Sortase A 5M (without a His-tag) 
purification and TEV protease cleavage.  
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Figure 3.4. Sortase activity of 6x-His SrtA 5M and TEV-cleaved SrtA 5M 
 
One N-terminal glycine is required for sortase-mediated labeling of EGFR KD 
We tested whether additional N-terminal glycines (Gly2-EGFR and Gly4-EGFR) are better 
substrates in the sortase-mediated reaction. Our results using the TAMRA-labeled LPETGG 
peptide showed that the labeling of Gly-EGFR, Gly2-EGFR, and Gly4-EGFR were very similar 
(figure 3.5). The addition of several N-terminal glycine residues had no effect on the efficiency 
of the reaction and all future experiments utilized one N-terminal glycine for the sortase-
mediated labeling reaction  
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Figure 3.5. Comparison of labeling of Gly-EGFR, Gly2-EGFR and Gly4-EGFR using an 
LPETG peptide substrate containing the TAMRA fluorophore. 
 
Inhibition of sortase enzymatic activity by metal chelators 
We tested the chelating effect of EDTA and EGTA at different concentrations of the metal 
chelators. Our results showed that both chelators at 10 mM concentration were sufficient in 
quenching the activity of sortase.  
Fluorophore-labeled EGFR KD has comparable kinase activity to wildtype 
Comparison of the kinase activity of a fluorophore-labeled EGFR kinase domain (Alexa568-
EGFR KD) shows similar fold of activation to the wildtype EGFR kinase domain (figure 3.6). 
We have consistently achieved a 10-12 fold of kinase activation of the fluorophore-labeled 
EGFR kinase domain on nickel liposomes, which is comparable to the activation of wildtype 
EGFR kinase domain. 
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Figure 3.6. Effect of fluorophore label on EGFR kinase domain activity and activation on 
nickel liposomes 
 
Affinity tagged peptide aids in post labeling purification of labeled EGFR KD and MSP 
protein 
N-terminal labeling of Gly-EGFR using sortase and a short peptide (that contains the fluorophore 
and the sortase recognition motif) initially resulted in <60% modification of the protein with the 
labeled peptide. This was due to the presence of unlabeled EGFR kinase domain (which differs 
from the labeled EGFR kinase, in molecular weight terms by the presence of a fluorophore) and 
could not be easily removed by gel filtration. We hypothesized that the addition of an affinity tag 
to the LPETG sortase substrate would enhance the purification of only the labeled protein. We 
designed a peptide that had a 6× histidine tag (for purification of labeled EGFR from unlabeled 
EGFR), a cysteine residue for maleimide labeling (we also utilized the NH2-amino group of the 
peptide for labeling with NHS-succinimidyl esters) and an LPETGG motif at the C-terminus. 
Labeling of Gly-EGFR with the H6-LPETGG peptide results in the regeneration of the sequence 
N-terminal to the EGFR that was cleaved off during TEV protease digestion (albeit subtle 
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mutations at the C-terminus of the peptide, ENLPETG instead of the original ENLYFQG).  
Figure 3.7 shows the use of this strategy to site specifically label TEV protease-cleaved EGFR 
KD with the H6-LPETGG peptide labeled with a quencher (CruzQuencherTM1 Maleimide). Our 
protein recovery from labeling 300 μg of EGFR was 140 μg, resulting in ∼50% protein yield. 
Using equation 1 above, we have consistently achieved >0.95 moles of dye per mole of protein 
in our purified labeled EGFR kinase domain.  
 
 
Figure 3.7. Coomassie-stained gel showing the labeling and purification of EGFR kinase 
domain using an LPETG peptide substrate containing CruzQuencher maleimide. Lanes; 1- 
Unlabeled EGFR KD, 2- Reaction mix after 30 mins, 3- Fraction from Gel filtration, 4- Eluted 
protein from Ni-NTA beads, 5- Final concentrated labeled protein 
We also used this labeling and purification strategy to modify MSP1E3D1 at the N-terminus 
using a fluorescein-labeled peptide. As shown in figure 3.8, we achieve >95% purity after 
purification and the fluorescent image confirms the presence of the fluorophore on the protein. 
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Figure 3.8. Coomassie and fluorescent gels showing the labeling and purification of MSP 
protein using the H6-LPETGG peptide substrate containing fluorescein. Lanes; 1- Unlabeled 
MSP, 2- Reaction mix after 30 mins, 3,4- Fractions from Gel filtration, 5- Eluted protein from 
Ni-NTA beads, 6- Final concentrated labeled protein. 
 
Figure 3.9. . Time course N-terminal labeling of EGFR KD using the H6-LPETGG peptide 
substrate labeled with fluorescein at two different positions. 
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3.6 DISCUSSION 
We have demonstrated that TEV-cleaved recombinant proteins are good substrates for SrtA. The 
use of TEV-cleaved proteins shows greater promise of practicality in biophysical and 
biochemical applications, but there remained the challenge of sub-stoichiometric protein 
modification due to back reaction and the reversible nature of sortase-mediated reactions. 
Addition of an affinity tag to the peptide substrate enables the efficient purification of labeled 
product, resulting in >95% purity. Although our strategy utilized the 6x histidine tag, which is a 
commonly used affinity tag for protein purification, we propose that the protocol can be made 
more stringent by employing two different affinity tags, one that is engineered into the protein of 
interest (prior to TEV protease cleave) and the other that is part of the fluorophore-containing 
peptide. The ability to site-specifically modify proteins with fluorophores to stoichiometric 
proportions is highly desirable for downstream biophysical studies.  
In our effort to obtain labeled EGFR kinase domains for biophysical studies, we tested different 
strategies which included maleimide labeling of cysteine residues, lipoic acid ligase-mediated 
click chemistry and sortase-mediated C-terminal labeling of EGFR kinase domain. The 
challenges we faced were two-fold; the temperamental behavior of the EGFR kinase domain 
where multiple rounds of cysteine-to-serine mutations compromised its enzymatic activity and 
activation on nickel liposomes, and the tolerance of the kinase domain to reaction conditions. 
While developing this robust labeling strategy, we realized that the sortase enzyme was still 
active after loading the labeled products onto a size exclusion chromatography column. Since 
this sortase A construct is calcium dependent, we demonstrated that molar equivalents of EDTA 
or EGTA was sufficient to kill the activity of sortase. In addition, while a stretch of N-terminal 
glycines can be used for the nucleophilic attack of the sortase-peptide intermediate, we have 
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shown that one glycine residue was enough to allow this reaction to proceed. An interesting 
discovery was the time needed for TEV protease cleavage of EGFR kinase domain. Standard 
TEV protease protocols require overnight incubation (at least 16 hrs), which can be detrimental 
to certain proteins. In our initial experiments, kinase activity assays of TEV-cleaved EGFR 
kinase domains (incubated overnight) showed diminished enzymatic activities compared to the 
wildtype EGFR. We have been able to optimize the conditions to minimize the incubation time 
for TEV protease cleavage (currently 6 – 8 hrs is required to efficiently cleave the EGFR kinase 
domain). However, we do experience ~50% loss in yield of the cleaved EGFR protein after the 
reverse nickel purification process, a challenge we are working on to improve the yield. Lastly, 
the H6-LPETGG peptide was carefully designed to enable the regeneration of the sequence 
proximal to the EGFR kinase domain. Though not entirely understood, our data suggests that the 
location of the fluorophore within this affinity peptide might enhance the fluorescent properties 
of the labeled protein (Figure 3.9). We realized that the N-terminally labeled fluorophore peptide 
exhibited greater fluorescence compared to the internal cysteine-labeled fluorophore peptide. 
This might be attributed to the interaction of the fluorophore with the protein, depending on its 
position and orientation. 
The epidermal growth factor receptor, EGFR has been the archetypical protein for studying 
receptor tyrosine kinases. EGFR and its orthologues (HER2, HER3 and HER4) have been known 
to play significant roles in tumorigenesis. Our site-specific fluorophore-labeled EGFR kinase 
domain offers a biological tool that can be used to answer mechanistic questions regarding 
protein-lipid and protein-protein interactions by receptor tyrosine kinases. Since these proteins 
are integrated into the membrane, the major challenge relates to careful selection of a 
fluorophore that exhibits similar optical properties in the presence and absence of the lipid 
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environment. Further, the development of the nanodisc technology by Sligar and colleagues has 
allowed for biophysical studies of proteins in a native bilayer environment. We have 
demonstrated the generality and applicability of this labeling strategy to other proteins by 
labeling the membrane scaffold protein MSP1E3D1 using sortase. MSP constructs are used to 
make nanodiscs and MSP1D1 has been site-specifically labeled using sortase and a fluorescein-
labeled depsipeptide (123). MSP1E3D1 in particular generates a 12.1 nm bilayer disc and has 
been useful in solubilizing and studying membrane proteins in their functional forms (124). Our 
fluorescein-labeled MSP1E3D1 broadens the utility and applicability of nanodiscs by providing 
a toolbox to use bulk and single molecule fluorescent spectroscopy to study conformational 
dynamics and macromolecular interactions between lipids and proteins.  
In conclusion, the N-terminal amino group offers unique functional properties for site-specific 
labeling of proteins. Our N-terminal labeling strategy provides a robust and straightforward 
protocol for functionalizing TEV protease cleaved recombinant proteins via a sortase-mediated 
reaction 
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Chapter 4: Biophysical characterization of EGFR kinase domain 
dimerization on lipid membranes  
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4.2 ABSTRACT  
The EGFR family of transmembrane receptor tyrosine kinases consists of EGFR, Her2, Her3 and 
Her4
 
that are known to play significant roles in tumorigenesis. Their kinase domains form 
asymmetric homo- and heterodimers necessary for activation, and leading to many downstream 
signaling cascades. While these family members share a common architecture with high 
sequence homology and structural similarity, the signaling potency of the different dimer pairs is 
dependent on their dimerization partner. Though crystallographic studies have elucidated the 
structures of EGFR homodimers, our current understanding of how the various heterodimers are 
organized in three-dimensional space has been the result of cell biological and in vitro 
biochemical assays. Our lab has shown that inhibition of Her3-Her2 heterodimers by Mig6 (an 
endogenous protein) is significantly weaker than the other dimer pairs, with Mig6 having a lower 
binding affinity to Her3. In addition, identification of mutations for all family members has 
necessitated research into determining how interactions at the molecular level contribute to 
activation. We hypothesized that structural differences at the dimer interface are one of the 
factors controlling the functional characteristics of the different dimer pairs. We use a 
combination of site-directed mutagenesis, in vitro kinase assays, biochemical and biophysical 
approaches especially Fluorescence Resonance Energy transfer to directly measure EGFR kinase 
domain dimerization on lipid surfaces. Our results using a dimerization-deficient control shows 
that our current Nickel liposome system may not be a suitable system for measuring dimerization 
of EGFR kinase domains on lipid membranes. 
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4.3 INTRODUCTION 
Abnormal signaling through the receptor tyrosine kinase of human EGFR family members 
underlies many cancer tumors (10). This family of proteins includes EGFR, HER2, HER3 and 
HER4 (3). All the members of the EGFR family share a common architecture: a large 
extracellular domain, a single alpha helical transmembrane segment, an intracellular domain 
containing the Tyr kinase domain (except HER3), and an unstructured C-terminal tail with 
tyrosine autophosphorylation sites (4-7). With the exception of HER2, all three family members 
are activated by ligand binding. Although HER3 has been regarded as a pseudokinase over the 
past few years, recent studies have shown that its kinase domain contains a low 
activity compared with the other three family members (4, 9). Ligand activation in the EGFR 
family of proteins leads to receptor homo- and heterodimerization, and autophosphorylation of 
tyrosine residues in the C- terminal region that provide docking sites for Src homology-2 or 
other signaling molecules that contain phosphotyrosine-binding domains. This initiates a 
cascade of signaling events that traverses the cytoplasm to communicate with the nucleus and the 
cytoskeleton (11-14). Recent structural and mutational studies have shown that an allosteric 
mechanism is necessary for activation by EGFR family dimers. This requires an interaction 
between the C-lobe of one kinase monomer (activator kinase/donor monomer) and N-lobe of the 
other monomer (receiver kinase/acceptor monomer). Alteration in the surface contact residues in 
the N-lobe region in Her3 means that it can only serve as an activator in a heterodimeric pair (4). 
Despite sequence and structural similarity, homo- and heterodimeric pairs of this family exhibit 
distinct signaling potencies. Studies have shown that Her2 is the preferred signaling partner for 
EGFR and HER3 with the HER2-HER3 heterodimers forming a potent signaling pair. Functional 
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characterization has shown the dependence of the heterodimeric partners for efficient oncogenic 
transformation (20). Using in vitro biochemical approaches, our lab has shown that an 
endogenous protein, Mig6, inhibits HER2-HER3 heterodimers to a lesser extent compared with 
its inhibition of other HER2 heterodimers (Figure 4.1). Mig6 binds to the distal surface of the C-
lobe of the kinase domain and inhibits dimerization (39). However, how molecular interactions 
at these dimeric interfaces impact the function of EGFR signaling is not fully understood. 
Whereas structural data can form the basis of the design of drugs to these receptors, effective 
therapeutic interventions would necessitate the accurate measurement of binding affinities and 
kinetic parameters inherent in protein-protein interactions in the EGFR family of kinases. We 
propose a quantitative approach to measure EGFR family kinase domain dimerization. This 
would provide direct experimental data regarding thermodynamic and kinetic parameters that 
govern EGFR dimerization. We will focus mainly on the kinase domain as our starting point 
since 1) it serves as a link between the extracellular domain and the C-terminal tail for activation 
and phosphorylation of other proteins, and 2) it gives us a baseline of significant experimental 
data that would enable us make predictions about how addition of other regions (such as the 
juxtamembrane domain and C-terminal tail) may impact dimerization and guide us to test these 
regions. Determination of these parameters with regards to how the kinase domain mutants 
interact with other family members will inform the field on the mechanism involved in the 
altered activation and signaling differences exhibited by these mutants.  
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Figure 4.1 Mig6 inhibition of HER2 heterodimers 
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4.4 METHODS 
Plasmids 
DNA encoding residues 696–1022 of the human epidermal growth factor receptor was cloned 
into pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites. This EGFR 
wildtype kinase domain construct contains an N-terminal 6-His tag, a linker, and a TEV protease 
cleavage site (MSYYHHHHHHDY DIPTTENLYFQGAM). Multisequence alignment of the 
EGFR family of proteins shows that their kinase domains contain seven cysteine residues, five of 
which are conserved (figure 4.2). The six cysteines in the EGFR kinase domain were mutated to 
serines, either individually or in combination. The nomenclature of the six cysteines was made to 
reflect conservative cysteines in our prior fluorophore labeling studies of the HER4 kinase 
domain. Table 4.1 and figure 4.3 provides the nomenclature and position of the cysteines in the 
structure of the kinase domain, respectively. Site-directed mutagenesis of cysteines was done 
using the QuikChange kit (Stratagene). Each construct was verified by DNA sequence analysis. 
We also used an in-fusion method to insert a DNA sequence at the C-terminus of the EGFR 
kinase domain, the expression of which generates an EGFR kinase domain containing an LPETG 
motif at the C-terminus. This insertion was also confirmed by DNA sequence analysis. 
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Figure 4.2. Multisequence alignment of the kinase domains of EGFR family members 
 
Cysteine 
residue 
Nomenclature Notes 
Cysteine-775 C0 NA 
Cysteine-781 C1 Close proximity to dimer interface 
Cysteine-797 C2 Reacts irreversibly with therapeutic inhibitors 
Cysteine-818 C3 NA 
Cysteine-939 C5 NA 
Cysteine-950 C6 NA 
 
Table 4.1. Nomenclature of cysteine residues in the EGFR kinase domain 
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Figure 4.3. Cysteine residues in the kinase domain of wildtype EGFR. This figure was 
generated using PYMOL and the 2GS2 EGFR crystal structure 
  
Expression and purification of EGFR KD Cysteine-to-Serine mutants 
We expressed and purified the EGFR kinase domain cysteine-to-serine mutants using a protein 
expression protocol described previously (4, 36). Recombinant bacmids (Bac-to-Bac expression 
system, Gibco BRL) were transfected into Spodoptera frugiperda Sf9 cells to produce 
recombinant baculovirus, which were used to infect Sf9 cells grown at 27 °C and 120 rpm in 
IPL-41 medium (Invitrogen) supplemented with 10% bovine calf serum supplemented 
(Hyclone), yeastolate extract (Invitrogen), penicillin, streptomycin, and Pluronic F-68. Cultures 
at a density of 1 x 10
6 
cells/ml were infected at 1 MOI and cells were harvested 48 – 72hours 
post infection by centrifugation at 6000 rpm and resuspended in Buffer A (25 mM Tris-HCl, pH 
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8, 300 mM NaCl, 10 mM imidazole, 5% glycerol, 1 mM DTT) supplemented with 
phenylmethylsulfonyl fluoride, benzamidine, DNase, and protease inhibitor mixture tablets 
lacking EDTA (Roche). The cells were homogenized using a probe sonicator and the lysate was 
centrifuged at 20000 rpm for 45 mins. 0.5 - 0.75 ml of Ni-NTA beads (Qiagen) were added to 
the supernatants and incubated on a rotator for 1 h at 4 °C. The beads were poured into a 10-ml 
disposable column (Bio-Rad) and the flow-through collected. The column was washed with 10 
column volumes of Buffer A + 20 mM imidazole, and the proteins were eluted with Buffer A + 
50–125 mM imidazole. The eluted fractions were further purified by gel filtration 
chromatography on a Superdex 200 GL 10/300 column (GE Healthcare) using 20 mM Tris-HCl, 
pH 8, 150 mM NaCl, 1 mM DTT buffer. 
LplA ligase/Click Chemistry conditions on EGFR KD activity 
We used an already published protocol to determine the effect of click chemistry conditions on 
the enzymatic activity of EGFR kinase domain (125, 126). 50 M of EGFR kinase domain was 
mixed with 100 M CuSO4, 0.5 mM Tris(3-hydroxypropyltriazolyl-methyl)amine, 5 mM 
Sodium ascorbate, 5 mM Aminoguanidine in buffer containing 100 mM potassium phosphate, 
pH 7.0 and 100 mM NaCl in a 2ml Eppendorf tube. The tube was closed and attached to a 
rotisserie and the reaction allowed to proceed for 1 hr. An aliquot of the final reaction was taken 
and the kinase activity determined, along with positive and negative controls. Positive control 
included the untreated wildtype EGFR kinase domain while negative controls included reactions 
that had one or more components omitted. 
Design and fluorophore-labeling of oligoglycine peptides for C-terminal labeling 
We used solid-phase synthesis to make two different oligoglycine peptides; GGGK and 
GGGCGGAWSHPQFEK. The eight-amino acid sequence, WSHPQFEK is a strep tag and 
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interacts with a specially engineered streptavidin construct called strep tactin. Following 
cleavage from the resin, the final crude oligoglycine peptides were purified by reversed-phase 
HPLC on a C18 column using a 10 – 70 % Buffer B (H2O, Acetonitrile and 0.05% TFA) 
gradient over 15 mins. The fractions were analyzed by LC/MS and the desired fractions were 
pooled together and lyophilized to dryness. The lyophilized peptides were reconstituted into 
water and the pH adjusted to around 8. Three molar equivalents of fluorescein or QSY7 
maleimide (in DMSO) were added to 5 mg of peptide in 50 mM Tris-HCl, pH 7.3 and 150 mM 
NaCl, and incubated at room temperature overnight. The labeled peptides were purified, 
analyzed and lyophilized using the same method described above. Measurement of the 
absorbance of the peptide and fluorophore at 280 nm (A280 and Amax, respectively) and their 
molar extinction coefficients (εprotein and εmax, respectively), allowed us to calculate the peptide 
concentration and degree of labeling using equation 1 below; 
  
𝐷𝑂𝐿 =  
𝐴𝑚𝑎𝑥 ∙ 𝜀𝑝𝑒𝑝𝑡𝑖𝑑𝑒
(𝐴280 −  𝐴𝑚𝑎𝑥  ∙  𝐶𝐹280) ∙ 𝜀𝑚𝑎𝑥
 
 
The correction factor (CF) is included in this equation to account for the absorption of 
fluorophore at 280 nm and equals the A280 of the dye divided by the Amax of the dye. 
C-terminal fluorophore labeling of EGFR KD using Fluorescein-labeled GGGK peptide 
A solution containing 25 M of EGFR kinase domain (containing the LPETG sortase 
recognition motif at the C-terminus), 6 M sortase and 0.5 mM fluorescein-labeled GGGK 
peptide was mixed together in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 
mM CaCl2. The reaction was incubated at 4 C for 30 mins in the dark. This was loaded onto a 
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Superdex 75 GL 10/300 column (GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 
mM DTT buffer. Fractions containing EGFR kinase domain were pooled together, concentrated 
and snap-frozen at -80 C. Aliquots were taken at this step and analyzed by SDS-PAGE followed 
by Coomassie staining. The controls included were: EGFR kinase domain (containing the 
LPETG sortase recognition motif at the C-terminus) only, sortase only, fluorescein-labeled 
GGGK peptide only, EGFR kinase domain (containing the LPETG sortase recognition motif at 
the C-terminus) and sortase, EGFR kinase domain (containing the LPETG sortase recognition 
motif at the C-terminus) and fluorescein-labeled GGGK peptide, sortase and fluorescein-labeled 
GGGK peptide. 
C-terminal fluorophore labeling of EGFR KD using Fluorescein and QSY7-labeled 
GGGCGGAWSHPQFEK peptide 
A solution containing 25 M of EGFR kinase domain (containing the LPETG sortase 
recognition motif at the C-terminus), 6 M sortase and 0.5 mM fluorescein-labeled 
GGGCGGAWSHPQFEK peptide was mixed together in a buffer containing 50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 10 mM CaCl2. The reaction was incubated at 4 C for 30 mins in the 
dark. This was quenched with 10 mM EDTA and loaded onto a Superdex 75 GL 10/300 column 
(GE Healthcare) using 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT buffer. Pooled 
fractions containing the EGFR kinase domain was incubated with 100 l of strep tactin II beads 
at 4 C for 30 mins. Fluorescein-labeled EGFR was eluted with 2.5 mM desthiobiotin, buffer 
exchanged into Buffer A (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) and 
concentrated to ~ 1 mg/ml. Aliquots were taken at each step of the process and analyzed by SDS-
PAGE. We determined the concentration and degree of labeling of the fluorescein-labeled EGFR 
using equation 1, where peptide is replaced with protein in the equation.  
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Design and fluorophore-labeling of peptides for N-terminal labeling 
We designed, synthesized, and purified a 25-mer peptide, 
MSYYHHHHHHDYDIPTCENLPETGG (or H6-LPETGG peptide). The internal cysteine was 
labeled with different maleimide fluorophores, depending on the downstream application. The 
maleimide fluorophores used were Alexa350, Alexa488, Alexa568 and fluorescein. Three molar 
equivalents of fluorophore were made to react with one molar equivalent of peptide at room 
temperature overnight. The resulting labeled peptides were purified, analyzed and lyophilized 
using the method already described. The degree of labeling was calculated using equation 1.  
N-terminal fluorophore labeling of EGFR KD 
The method used to site-specifically fluorophore label the EGFR kinase domains at the N-
terminus using a sortase-mediated reaction has been described exhaustively in chapter 3. 
LPETGG peptides labeled with any of the four fluorophores (Alexa350, Alexa488, Alexa568 or 
fluorescein) was incubated with Gly-EGFR and sortase in a buffer containing 50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, and 10 mM CaCl2 under similar reaction conditions and reagent molar 
equivalents, as described already. Fluorophore-labeled EGFR kinase domains were concentrated 
to ~1 mg/ml and the degree of labeling calculated using equation 1. 
Kinase activity of EGFR KD mutants and fluorophore-labeled EGFR KD 
The protocol used to measure the kinase activities of labeled EGFR KDs, both in solution and on 
Nickel liposomes (to induce dimerization) have been described in Ref 36. Wildtype or 
fluorophore-labeled EGFR KDs were incubated in 20 mM Tris, pH 7.5, 10 mM MgCl2, 100 M 
Na3VO4, 2 mM DTT, 100 M ATP, 1 Ci of [- 32P] ATP, 60 mM NaCl, 5% glycerol in 25-l 
total reaction volume. The reaction was initiated by the addition of 1.25 M kinase, incubated at 
30 C for 6 mins and quenched with EDTA. 100 g of avidin was added to the samples and 
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transferred to centrifugal filtration units with 30,000 molecular weight cutoff (Millipore). The 
samples were washed four times with 0.5 M sodium phosphate, 0.5 M NaCl, pH 8.5 and the 
retained 
32
P measured by scintillation counting. The kinase activity on liposomes were measured 
by incubating the wildtype and fluorophore-labeled EGFR KDs on ice for 15 mins before 
initiating the reaction. Total lipid concentration was 0.5 mg/ml. Samples tested included EGFR 
KD wildtype, Gly-EGFR KD, Fluorescein-labeled EGFR KD, Alexa488-labeled EGFR KD, 
Alexa568-labeled EGFR KD, CruzQuencher-labeled EGFR KD, EGFR KD (with an LPETG 
motif at the C-terminus), and EGFR KD labeled with either GGGK-fluorescein, 
GGGCGGAWSHPQFEK-fluorescein or GGGCGGAWSHPQFEK-QSY7 at the C-terminus. 
FRET assay using Alexa488-labeled-EGFR and Alexa568-labeled EGFR 
1M Alexa488-labeled EGFR KD was mixed with 1M or 2M of Alexa568-labeled EGFR KD 
in a buffer containing 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM DTT or Nickel liposomes. 
The total volume of the mixture was 22l. This was incubated on ice for 20mins, aliquoted into 
384 corning plate wells and placed in an Infinite M200 Microplate reader. The mixture was 
excited at 490nm and fluorescent measurements taken over a wavelength range between 520nm 
and 620nm. Controls included Alexa488-labeled EGFR KD(V-R dimerization-deficient mutant) 
in buffer or on nickel liposomes, Alexa568-labeled EGFR KD(V-R dimerization-deficient 
mutant) in buffer or on nickel liposomes, Alexa488-labeled H6-LPETGG peptide in buffer or on 
nickel liposomes, Alexa568-labeled H6-LPETGG peptide in buffer or on nickel liposomes and 
nickel liposomes only. 
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4.5 RESULTS 
EGFR kinase domain Cysteine mutants have diminished kinase activity 
The enzymatic kinase activity of EGFR kinase domain was to determine the structural and 
functional integrity of the cys-ser mutants. We measured the phosphorylation of a biotinylated 
degenerate peptide by the cys-ser mutants. Compared to wildtype EGFR kinase domain, four of 
the singly mutated cys-ser constructs showed similar kinase activity. However, mutations at two 
key cysteine residues (C1 for Cys781 and C2 for Cys797) resulted in abrogation of the kinase 
activity. We made triple, quadruple and quintuple constructs that contained those cys-ser mutants 
that showed appreciable kinase activity. We also tested mutating C1 to alanine and C2 to 
aspartate and asparagine. Our data suggests that combination of these cysteine mutations in the 
quintuple mutant resulted in very low kinase activity compared to the wildtype (Figures 4.4 to 
4.11) 
 
Figure 4.4. Effect of single cysteine mutation (EGFR C0, C1 and C2) on kinase activity and 
activation on liposomes. Cysteines at respective residues were mutated to serines.  
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Figure 4.5. Effect of single cysteine mutation (EGFR C3, C5 and C6) on kinase activity and 
activation on liposomes. Cysteines at respective residues were mutated to serines.  
 
 
Figure 4.6. Effect of triple (C0C5C3) and quadruple (C0C5C3C2) cysteine mutations on 
kinase activity and activation on liposomes. Cysteines at respective residues were mutated 
to serines.  
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Figure 4.7. Effect of single (C1, C-A) and quadruple (C0C5C3C2) cysteine mutations on 
kinase activity and activation on liposomes. In the quadruple mutant, all cysteines have 
been mutated to serines, while in the single mutant, cysteine at position C1 has been 
mutated to alanine.  
 
Figure 4.8. Effect of cysteine mutation at the C2 position in the quadruple mutant 
(C0C5C3C2) on kinase activity and activation on liposomes. Apart from the C2 positions 
that have been mutated to alanine, aspartate or asparagine, all other cysteines at the other 
positions have been mutated to serine.  
89 
 
 
Figure 4.9. Effect of cysteine mutation at the C2 position in the quadruple mutant 
(C0C5C3C2) on kinase activity and activation on liposomes. Comparing cysteine to serine 
or cysteine to asparagine mutation at the C2 position in the quadruple mutant.  
 
Figure 4.10. Effect of cysteine mutation at the C1 and C2 positions in two quadruple 
mutants (C0C5C3C2 and C0C5C3C1) on kinase activity and activation on liposomes. In 
the C0C5C3C1 mutant, the C1 has been mutated to alanine while all other cysteines are 
mutated to serine. In the C0C5C3C2 mutants, C2 is either mutated to aspartate or 
asparagine while the three other cysteines are mutated to serines.  
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Figure 4.11. Effect of EGFR kinase domain pentamutant (C0C5C3C2C1) on kinase activity 
and activation on liposomes. While the other three cysteines (C0C5C3) have been mutated 
to serines, C1 is mutated to alanine while C2 is mutated to asparagine. 
 
LplA ligase/Click chemistry conditions inhibit EGFR KD activity 
We subjected the EGFR kinase domain to conditions that were required for click chemistry using 
LplA ligase. We also excluded some components of the reaction mixture to determine the effect 
of those components on the activity of EGFR KD. After 60 minutes of reaction, we measured the 
kinase activity of EGFR KD with and without the click chemistry components. Figure 4.12 
shows that the addition of CuSO4, sodium ascorbate and THPTA results in the loss of kinase 
activity.  
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Figure 4.12. Kinase activity of EGFR kinase domain with LplA ligase and CuAAC 
conditions. EGFR WT, EGFR wildtype , EGFR WT click, EGFR wildtype mixed with 
CuSO4, Tris(3-hydroxypropyltriazolyl-methyl)amine, Sodium ascorbate, Aminoguanidine 
in buffer, EGFR w/o copper, EGFR wildtype mixed with, Tris(3-hydroxypropyltriazolyl-
methyl)amine, Sodium ascorbate, Aminoguanidine in buffer, EGFR w/o AG, EGFR 
wildtype mixed with CuSO4, Tris(3-hydroxypropyltriazolyl-methyl)amine, Sodium 
ascorbate in buffer. 
 
C-terminal fluorophore-labeled EGFR KD has low kinase activation 
Following successful elution of the labeled EGFR-LPETG with fluorescein-labeled 
GGGCGGAWSHPQFEK peptide, our calculations resulted in >95% purity after the post-
labeling purification. We obtained similar results when EGFR-LPETG was labeled with the 
QSY-labeled GGGCGGAWSHPQFEK peptide. We also compared the kinase activity and 
activation on nickel liposomes of EGFR KD WT to the labeled and unlabeled EGFR-LPETG. 
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The results show a diminished kinase activity and activation of the EGFR-LPETG (and 
fluorescein-labeled and QSY-labeled EGFR) as compared to wildtype (4.13) 
 
Figure 4.13. Effect of EGFR kinase domain C-terminal modifications on kinase activity and 
activation on liposomes. Samples; EGFR WT, EGFR wildtype, EGFR-lpetg, EGFR 
wildtype engineered with LPETG sortase recognition motif, FL-lpetg, EGFR wildtype 
engineered with LPETG sortase recognition motif and labeled with fluorescein at the C-
terminus, EGFR-GGGK, EGFR wildtype engineered with LPETG sortase recognition 
motif and labeled with GGGK peptide, QSY-lpetg,  EGFR wildtype engineered with 
LPETG sortase recognition motif and labeled with QSY quencher at the C-terminus. 
 
N-terminal fluorophore-labeled EGFR KD has comparable kinase activity to wildtype 
We designed and synthesized an affinity tag-containing peptide that was labeled with a 
fluorophore. This was used to label a TEV protease cleaved EGFR KD (g-EGFR) that generates 
a nucleophilic glycine necessary for the sortase reaction. For detailed results of the challenges, 
drawbacks and breakthroughs involved in successful labeling of EGFR KD at the N-terminus 
with a fluorophore, please refer to chapter 3. Initially, when we compared the kinase activities 
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and activation of fluorescein-labeled EGFR to wildtype EGFR, the data showed that the labeled 
EGFR kinase domains had comparatively lesser activity and lowered fold activation on nickel 
liposomes. We subjected the wildtype EGFR KD to a mock TEV protease digestion (containing 
no TEV protease), mock labeling (with no sortase) and subsequent purification with gel filtration 
and Ni-NTA columns. Here, we show that mock-labeled EGFR KD has similar activity and fold 
activation as labeled EGFR KD (Figure 4.14). We also show that fluorophore-labeled EGFR 
kinase domain retains activity, following the shortening of the time required for TEV protease 
cleavage and optimization of the purification steps (figure 4.15 and 4.16). These fluorophore-
modified EGFR kinase domains had 95% purify after labeling and our calculations show that 
there is a 1:1 fluorophore: protein ratio. 
 
 
Figure 4.14. Effect of TEV protease cleavage, labeling and purification conditions on 
EGFR kinase domain activity  
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Figure 4.15. Effect of fluorophore labeling on EGFR kinase domain activity. EGFR kinase 
domain was labeled with Alexa488 maleimide. 
 
 
Figure 4.16. Effect of fluorophore labeling on EGFR kinase domain activity. EGFR kinase 
domain was labeled with Alexa568 maleimide. 
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Alexa488-EGFR interacts with Alexa568-EGFR when in close proximity 
Following Nickel liposome incubation, the data shows a ~50% decrease in the donor (488-
EGFR) fluorescence and a ~35% increase in acceptor (568-EGFR) fluorescence as shown in 
figure 4.17A. This fluorescence change was also reflected in the calculated FRET ratios (Table 
4.2). Negative controls using dimerization-deficient EGFR KD (V924R mutant) labeled with the 
Alexa FRET pairs also showed increased FRET ratios on liposomes as observed with wildtype 
EGFR KD (Figure 4.17B). Lastly, peptide labeled with Alexa488 and Alexa568 produced data 
that suggested an increase in the FRET ratio on liposomes as compared to solution conditions. 
(figure 4.18) 
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Figure 4.17. FRET measurements using Alexa488- and Alexa568-labeled EGFR kinase 
domains. A. Measuring FRET using Alexa488- and Alexa568-labeled wildtype EGFR kinase 
domain. B.  Measuring FRET using Alexa488- and Alexa568-labeled dimerization-deficient 
EGFR kinase domain mutant (Val924Arg). 
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Figure 4.18. Effect of concentration of the fluorophore-labeled peptide alone on FRET 
measurements 
 
 FRET Ratio (Emission at 607nm/Emission at 530nm) 
 Buffer Nickel Liposomes 
EGFR KD 0.09 0.24 
EGFR KD (V924R) 0.1 0.20 
MSYY peptide 0.05 0.1 
 
Table 4.2. FRET ratios for EGFR kinase domain (and dimerization-deficient mutant) and  
           MSYY peptide. FRET ratio between 0.1 – 10 is considered a range that allows for  
           favorable efficiency calculations (127). 
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4.6 DISCUSSION 
The formation of an asymmetric dimer by EGFR (HER2, HER3 and HER4) kinase domains is 
critical for activation and subsequent phosphorylation of their C-terminal tails. Notwithstanding, 
mechanistic details regarding how these kinase domains dimerize is under investigation. Most 
importantly, questions regarding binding affinities and kinetics of dimerization remain 
unanswered. In this work, we attempted to develop a biological probe that can be used to directly 
measure EGFR kinase domain dimerization on lipid surfaces. Our approach was to develop an 
EGFR kinase domain construct that is site-specifically labeled with two fluorophores, either a 
fluorescent donor-acceptor FRET pair or a fluorophore-quencher pair.  Our enzymatic kinase 
activity results with EGFR kinase domain cysteine mutants suggested that two key cysteine 
residues (Cys781 and Cys797) were important for the structural and functional integrity of the 
kinase. These two cysteines have been shown to be solvent accessible (128) while Cys797 have 
been historically targeted by irreversible kinase inhibitors. The advent of chemoenzymatic 
approaches allowed us to take advantage of a sortase-mediated approach to site-specifically 
fluorophore-label the EGFR kinase domain at the C- and N-terminus. Unfortunately, C-terminal 
labeling compromised the activation of the kinase. X-ray crystal structures show little to no 
density of the distal region following the kinase domain core. From our analysis, we propose that 
this region is close to the dimer interface and its alteration would have deleterious effects on the 
structure and function of the kinase. The N-terminally labeled kinase domain provided an 
excellent opportunity for use in developing quantitative approaches to measure dimerization. We 
tested various donor-acceptor FRET pairs and a fluorophore-quenching system to develop this 
dimerization assay. Our findings suggest that the fluorophores interact differently with the nickel 
liposomes and this posed a huge challenge in establishing the requisite parameters for the assay. 
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During the development of this assay with Alexa488 and Alexa568, we obtained appreciable 
signal changes when EGFR kinase domains were incubated on liposomes. This result was 
encouraging and provided preliminary evidence that the kinase domains incubated on nickel 
liposomes were within a distance that allowed for transfer of energy. However, rigorous negative 
control experiments with the dimerization-deficient mutant (Val924Arg) and the fluorophore-
labeled peptide produced similar FRET results. The ability of the fluorophore-labeled peptide to 
FRET (in the absence of EGFR kinase domain) shows that the assay might be measuring the 
proximity of the peptides or proteins and not the transfer of energy. In fact, incubation on nickel 
liposomes allows the concentration of the his-tagged EGFR KD, perhaps favoring 
conformational changes that result in dimerization and subsequent activation. Although my 
working concentration (protein) for my FRET assay is 1-2uM, this value translates to 1-2mM 
local concentration of EGFR KD on liposomes (4). At such high concentrations, the fluorophore 
pairs in the linker region are poised to FRET irrespective of the presence or absence of proteins. 
In conclusion, this study presents a basis for further research to develop a biological probe to 
measure EGFR kinase domain dimerization on lipid surfaces. While the nickel liposome/his-
tagged kinase domain system presents challenges for directly measuring dimerization affinities, 
our single-site fluorophore-labeled EGFR kinase domain can be useful in developing a different 
optical-based assay to determine how these proteins interact. For instance, we have successfully 
labeled the EGFR kinase domain containing the juxtamembrane segment with a FRET pair. 
Since studies have shown that the JM can dimerize without the need of lipid membranes (46), we 
can use this labeled JM construct and equilibrium studies (analytical ultracentrifugation) to 
monitor EGFR kinase domain dimerization in solution. 
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Chapter 5: Conclusion and Future Directions 
 
 
 
 
 
 
 
 
 
 
101 
 
5.1 Conclusion and future perspectives 
The biology of the EGFR family of receptor tyrosine kinases is intimately connected to the 
structural organization of the different domains of these proteins. A deeper understanding of 
these structures has aided the development of therapeutics that target different structural states of 
both the extracellular and intracellular domains. However, the field has not made enough 
advancement in characterizing the C-terminal tails and dissecting their unique structural features. 
In this work, we provide experimental data that improves our basic understanding of the C-
terminal tails in isolation. We also initiate experiments to build a platform that would enable the 
quantitative measurement of kinase domain dimerization on lipid surfaces using site-specifically 
fluorophore-labeled EGFR protein constructs.  
We are the first to provide a comprehensive and detailed biophysical analysis of the C-terminal 
tail of a receptor tyrosine kinase. In chapter 2, we use multiple biophysical approaches to 
produce convincing experimental data that the EGFR and HER3 C-terminal tails are intrinsically 
disordered. Since the discovery of EGFR and its involvement in several human cancers, the field 
has made tremendous progress towards elucidating the structures of the various domains and 
enhancing the development of therapeutics against EGFR and HER2 using these structures. Our 
results provide stimulating impetus to investigate the dynamics of the C-terminal tails. Although 
the C-terminal tails have comparable molecular weights to globular proteins, their apparent size 
using the biophysical tools, are usually bigger than their globular counterparts. In fact, our data 
using SAXS shows that the EGFR C-terminal tail assumes greater shape and size compared to 
the compact, globular kinase domain. Such dynamic and flexible characteristics of the C-
terminals are very important, given that they provide docking sites and interacting surfaces for 
multiple proteins to bind.  
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Several outstanding questions remain regarding the C-terminal tails. There is no structural or 
biophysical information regarding the interaction of kinase domain and the C-terminal tail, prior 
to activation. We have attempted to use Isothermal Calorimetry to determine the Kd of the tail 
interacting with the kinase domain and have been unsuccessful. Given that these intrinsically 
disordered regions have high on- and off rates, it is often a challenge to determine these 
thermodynamic parameters. This is also compounded by the high molar ratios needed for this 
interaction, and often requires the C-terminal tails to be in excess, a situation that can lead to 
aggregation and difficulty in interpreting the data. Secondly, it is unknown how phosphorylation 
affects the shape, size and conformation of the EGFR and HER3 C-terminals. In certain proteins, 
it has been shown that there is a disorder-to-order transition following phosphorylation (129). 
Since this is not a general phenomenon, it is important to determine how phosphorylation affects 
the intrinsic disorder characteristics of these proteins. The challenge that remains is the 
stoichiometric phosphorylation of these tails and effective separation of the fully phosphorylated 
C-terminal tail from the partially and unphosphorylated species. We circumvented this by 
expressing and purifying a phosphomimetic mutant (EGFR Y-E), where all the nine tyrosines 
have been replaced with a glutamate residue. Preliminary SAXS measurements show that 
wildtype EGFR C-terminal and the EGFR Y-E mutant have similar Rg values, and that there 
might be no difference in size between the phosphorylated and unphosphorylated constructs. 
Further biophysical studies need to be done to accurately measure the size and shape of the 
phosphorylated species. A major criticism for using this strategy is that the Y-E mutant does not 
fully represent the phosphorylated state of EGFR. Another important question that remains 
unanswered is the significance of intrinsic disorder to the function of EGFR family of receptor 
tyrosine kinases. In this realm, it might be necessary to combine these in vitro experiments with 
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cell-based approaches to fully understand their importance. Since intrinsically disordered regions 
are enriched in polar residues and have less hydrophobic residues, it will be important to create 
mutants that are either less disordered or more disordered, and determine their effects in cell-
based assays on signaling outputs. 
Our study in chapter 3 provides a strategy that can be used to N-terminally label any recombinant 
protein that contains a TEV cleavage site proximal to the protein core, using sortase. We 
successfully use this sortase-mediated strategy to label two proteins, the EGFR kinase domain 
and MSP1E3D1, a membrane scaffold protein. The genomic and post-genomic eras necessitate 
the development of strategies for protein bioengineering and incorporation of a variety of 
modalities to proteins for basic science research, biotherapeutics and biotechnological utility. 
Protein modification approaches must be simple and robust, requiring shorter reactions times for 
labeling. Such strategies should be amenable to functionalizing proteins with different handles at 
any desired location with minimum structural and functional consequences. Most importantly, 
protein labeling methods must be efficient, which enables their utility for quantitative and other 
biophysical studies. A major challenge faced by labeling approaches pertains to the purity of the 
labeled protein, and the related removal of unlabeled species. The N-terminal amino group offers 
unique functional properties for site-specific labeling of proteins. Efficient labeling with N-
hydroxysuccinimide esters requires controlled pH experiments to selectively modify the N-
terminal amino group over lysine residues which is always challenging as a result of the 
closeness in pKa of the α-amino group of the protein versus the ε-amino group of lysine. Sortase 
fulfilled most of the requirements for chemoenzymatic modification of proteins, but still faced 
the challenge of sub-stoichiometric labeling. However, post-labeling purification using an 
affinity tag in the peptide substrate resulted in >95% purity of the labeled protein. Our strategy 
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enables the use of labeled proteins for biophysical and biochemical studies as well as for 
diagnostic purposes. 
In chapter 4, we employed the single-site fluorophore labeled EGFR kinase domain to develop a 
quantitative tool that can be used to measure dimerization on lipid surfaces. Our data suggests 
that the assay we developed was measuring the proximity of the kinase domains, rather than 
dimerization. This suggests that the nickel liposome system provides a platform that allows the 
population of histidine-tagged proteins and that dimerization might be occurring on these 
surfaces through a mechanism that is not completely understood, presumably altering the 
conformation of the kinase domain. While most studies have shed light on the structural features 
of the kinase domain and provided indirect measurement of the dimerization of kinase domains 
on lipid membranes, there needs to be further investigation regarding the direct measurement of 
dimerization and the determination of quantitative parameters that govern this. This would 
provide us with a molecular understanding of how EGFR kinase domain dimerizes. Such 
research provides signatures specific for each dimeric pair that would drive rational and 
structure-based design of therapies that target these dimeric interfaces. In fact, the crystal 
structure and chemical foot printing mass spectrometric analysis of the EGFR-HER3 and HER2-
HER3 dimers respectively (130,131), provides stimulating evidence for the field to initiate 
investigations that would enhance the development of inhibitors that target the dimer interface of 
homo- and heterodimers. Our lab and other groups have shown that certain cancer-associated 
mutations are close to the dimer interface of the kinase domain. A robust dimerization assay 
would enable us determine the effect of these activating mutations on dimerization. 
Determination of these parameters with regard to how the kinase domain mutants interact with 
other family members will inform the field on the mechanism involved in the altered activation 
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and signaling differences exhibited by these mutants. It also provides a baseline of significant 
experimental data that would enable us make predictions about how addition of other regions 
(such as the juxtamembrane domain and C-terminal tail) may impact dimerization and guide us 
to test these regions. 
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